New Groupon (GRPN) Payments™ Service Offers Local Businesses Low Credit Card Rates

Today Groupon (NASDAQ: GRPN) announced the launch of Groupon Payments™, a payments service backed by a guarantee to be the lowest cost option for the company’s merchants to accept credit cards. Built into the latest version of the Groupon Merchants app for the iPhone and iPod Touch, Groupon Payments provides restaurants, salons and spas, retail establishments and other local businesses with the ability to accept all credit card payments at a lower rate than other providers.

Groupon launches Groupon Payments(TM), a payments service backed by a guarantee to be the lowest cost option for the company’s merchants to accept credit cards. (Photo: Business Wire)

After a successful pilot in the San Francisco Bay Area, any merchant that runs a deal with Groupon in the United States can now accept payments at the lowest rates in today’s marketplace:

• Swiped transactions – MasterCard, Visa and Discover (1.8% plus $0.15 per transaction) and American Express (3% plus $0.15 per transaction)
• No hidden costs or monthly fees

Merchants will also have their credit card deposits in their bank accounts overnight, which is much faster than the typical experience of waiting two to three business days offered by most credit card processors.

“Our goal is to provide merchants with the most affordable and powerful tools to run and grow their businesses,” said Mihir Shah, VP Mobile and Merchant Products at Groupon. “With groundbreaking pricing and service, Groupon Payments does just that.”

Groupon merchants that sign up for the service will enjoy a fast, intuitive experience that is capable of tackling their everyday credit card processing needs. Some of the Groupon Payments characteristics include:

• Service — Backed by a 7-days-a-week Groupon Payments support team reachable by phone and email
• Hassle-Free — Enroll within minutes
• Fully-Featured — Use Groupon Merchants app to enter bill totals, add tips, apply taxes, process refunds and email customer receipts
• Sturdy — Swipe credit cards via a sturdy, case-based credit card reader suitable for high transaction volume merchants or an audio jack accessory
• Secure — Encrypted and secure credit card information
• Analytics — View payments information seamlessly to an online Payments Center where merchants can view a live transaction history, check daily sales reports, track deposits to their account and analyze revenue trends

In addition, merchants can use the app to scan and redeem Groupons and monitor additional spend over the value of the Groupon.

“While the cost savings are obvious, we were really impressed by the level of support provided by Groupon and the speed in which we received our payments,” said Nadia McClinton, owner of Body By X in Corte Madera, Calif. “From day one we discovered we could rely on Groupon Payments to effectively, quickly and easily process transactions and deliver a better customer and employee experience. It truly saves us time, money and effort that we can invest in other aspects of our operations.”

While Groupon Payments is designed for local businesses that run deals with Groupon, the service is also available as a pilot to non-Groupon merchants at the low rate of 2.2% (3% American Express) + $0.15 per transaction.

Groupon Payments and the payments-enabled Groupon Merchants app are the latest additions to Groupon’s extensive suite of products and services that merchants can use to save money, streamline operations and grow their businesses. These include: Groupon Daily Deals; Groupon Now! real-time location-based offers; Groupon Rewards an easy-to-use loyalty program and Groupon Scheduler an online scheduling application for appointment-based businesses.

Local businesses interested in learning more about Groupon Payments can visit www.GrouponWorks.com/Payments. The Groupon Merchants app can be downloaded for free from the iTunes App Store.

The guarantee of lowest possible rates is only available to Groupon merchants located in the United States. Merchants must provide proof of current third-party rates for identical services. Participation is subject to the terms of the Groupon Payments Merchant User Agreement which may modify or discontinue the guarantee and the underlying services at any time. The guarantee is void where prohibited by law.

About Groupon

Groupon (NASDAQ: GRPN) launched in November 2008 in Chicago, features a daily deal on the best stuff to do, eat, see and buy in 48 countries around the world. Groupon uses collective buying power to offer huge discounts and provide a win-win for businesses and consumers, delivering more than 1,000 daily deals globally. To subscribe for the best deals in your city, visit (http://www.groupon.com). To learn how to become a featured business, visit (http://www.grouponworks.com).

Forward-Looking Statements

This announcement contains forward-looking statements that involve risks and uncertainties, and actual results could differ materially from those discussed. Factors that could cause or contribute to such differences include, but are not limited to, the factors included under the headings “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the company’s Annual Report on Form 10-K for the year ended December 31, 2011 and subsequently filed quarterly reports filed with the Securities and Exchange Commission, copies of which may be obtained by visiting the company’s Investor Relations web site at http://investor.groupon.com or the SEC’s web site at (www.sec.gov). You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. Moreover, neither we nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements. We undertake no obligation to update publicly any forward-looking statements for any reason after the date of this press release to conform these statements to actual results or to changes in our expectations.

“Groupon” is a registered trademark of Groupon, Inc. All other names used may be trademarks of their respective holders.

Loncor (LON) Announces Financings

TORONTO, ONTARIO — (Marketwire) — 09/19/12 — Loncor Resources Inc. (the “Company” or “Loncor”) (TSX VENTURE:LN)(NYSE MKT:LON)(NYSE Amex:LON) announces that it has filed a preliminary short form prospectus in connection with a marketed offering of common shares of the Company (the “Offering”). The Offering will be conducted through a syndicate of investment dealers (the “Underwriters”). The price of each common share to be issued under the Offering will be determined in the context of the market.

Loncor will grant the Underwriters an over-allotment option to purchase a number of additional common shares of the Company equal to up to 7.5% of the aggregate number of common shares sold in the Offering to cover over-allotments and for market stabilization purposes, exercisable at any time up to 30 days after the closing of the Offering.

The preliminary prospectus is still subject to completion or amendment. A copy of the preliminary prospectus will be available electronically at www.sedar.com. There will not be any sale of or any acceptance of an offer to buy the securities until a receipt for the (final) prospectus has been issued.

Newmont Mining Corporation (“Newmont”) has expressed an interest in completing a non-brokered private placement of common shares of the Company at the Offering price, concurrent with and subject to completion of the Offering. The terms of this private placement are expected to be finalized once the terms of the Offering have been finalized. Newmont (through an affiliate) currently holds 9,700,000 (representing 16.35%) of the outstanding common shares of the Company and 1,000,000 common share purchase warrants of the Company, with each such warrant entitling the holder to purchase one common share of the Company at a price of Cdn$2.30 until December 2012. The Company expects that Newmont’s equity interest in the Company would increase to 19.99% on a fully-diluted basis upon completion of this private placement (and giving effect to the completion of the Offering).

The Company is targeting to raise total gross proceeds of approximately Cdn$12 million pursuant to the two financings.

Loncor intends to use the proceeds from the financings for the exploration and development of the Company’s mineral properties in the Democratic Republic of the Congo and for working capital and general corporate purposes.

Closing of the financings is subject to, among other things, receipt of all necessary regulatory approvals, including the approval of the TSX Venture Exchange and the NYSE MKT LLC.

This press release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended, (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

Loncor is a Canadian gold exploration company focused on two key projects in the Democratic Republic of the Congo (the “DRC”) – the Ngayu and North Kivu projects. The Company has exclusive gold rights to an area covering 2,087 sq km covering part of the Ngayu Archaean greenstone belt in Orientale province in the northeast portion of the DRC. Loncor also owns or controls 55 exploration permits in North Kivu province, covering 17,760 square kilometres, located west of the city of Butembo. Both areas have historic gold production. Led by a team of senior exploration professionals with extensive African experience, Loncor’s strategy includes an aggressive drilling program to follow up on initial known targets as well as covering the entire greenstone belt with regional geochemical and geophysical surveys. Additional information with respect to the Company’s projects can be found on the Company’s web site at www.loncor.com.

Forward-Looking Information: Statements in this press release relating to the proposed financings and the Company’s exploration and development plans are forward-looking information within the meaning of applicable Canadian securities laws. Forward-looking information is subject to a number of risks and uncertainties that may cause the actual results of the Company to differ materially from those discussed in the forward-looking information, and even if such actual results are realized or substantially realized, there can be no assurance that they will have the expected consequences to, or effects on the Company. Factors that could cause actual results or events to differ materially from current expectations include, among other things, failure to enter into definitive documentation in respect of, or complete, one or both of the proposed financings, the need to satisfy regulatory and legal requirements with respect to both financings, risks related to the exploration stage of the Company’s properties, market fluctuations in prices for securities of exploration stage companies, the location of the Company’s properties in the DRC, uncertainties relating to the availability and costs of financing needed in the future, the possibility that future exploration or development results will not be consistent with the Company’s expectations, failure to establish estimated mineral resources (the Company’s mineral resource figures are estimates and no assurance can be given that the indicated levels of gold will be produced), uncertainties related to fluctuations in commodity prices and equity markets and the other risks disclosed under the heading “Risk Factors” and elsewhere in the Company’s annual report on Form 20-F dated March 30, 2012 filed on SEDAR at www.sedar.com and EDGAR at www.sec.gov. Forward-looking information speaks only as of the date on which it is provided and, except as may be required by applicable securities laws, the Company disclaims any intent or obligation to update any forward-looking information, whether as a result of new information, future events or results or otherwise. Although the Company believes that the assumptions inherent in the forward-looking information are reasonable, forward-looking information is not a guarantee of future performance and accordingly undue reliance should not be put on such information due to the inherent uncertainty therein.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contacts:
Loncor Resources Inc.
Peter N. Cowley
President and Chief Executive Officer
+ 44 (0) 790 454 0856

Loncor Resources Inc.
Arnold T. Kondrat
Executive Vice President
+ 44 (0) 790 454 0856

Loncor Resources Inc.
Naomi Nemeth
Investor Relations

Prana’s (PRAN) PBT2 Clinical Trials Cited as Most Advanced in Neurodegeneration

Prana’s PBT2 Clinical Trials Cited as Most Advanced in Addressing Neurodegeneration From the Metal Equilibrium Perspective

MELBOURNE, AUSTRALIA — (Marketwire) — 09/19/12 — Prana Biotechnology (NASDAQ: PRAN) (ASX: PBT) today reported that it had been cited in an interview in The Life Sciences Report with George Zavoico, Ph.D., senior equity analyst and managing director with MLV & Co., as the only drug company to address in clinical trials the control of transition metal levels in neuronal synapses, a key event in age-related dysfunction of the brain. The Report citing Prana is titled, “Seven Innovative Biotechs That Could Soar By Year-End”.*

In the published interview, Dr. Zavoico spoke about an emerging hypothesis addressing the formation of beta amyloid plaques, and how another neuronal protein, tau, is hyperphosphorylated, enabling it to form neurofibrillary tangles. These are recognized by experts in the field as key events in age-related brain dysfunction and cognitive loss. The basis for what has been called the “Metals Dyshomeostasis Hypothesis” is the abnormal distribution and loss in the control of transition metal levels in neuronal synapses. Dr. Zavoico said, “Metals like zinc, copper and iron have a number of important biologic functions, most notably in the function of numerous enzymes and receptors. Zinc, in particular, binds to beta amyloid, leading to its aggregation and, ultimately, plaque formation”.

Moreover, studies have shown that abnormal distribution of transition metals driven partly by beta amyloid plaque formation affects the function of tau, an intracellular protein essential for normal neuronal function. Tau becomes hyperphosphorylated and forms neurofibrillary tangles, which is thought to cause neuronal cell death.

Prana is evaluating the potential clinical benefit of PBT2 in two Phase II trials in two different neurodegenerative diseases. In Alzheimer’s disease, the IMAGINE trial, a double blind placebo controlled trial enrolling 40 patients with prodromal or mild Alzheimer’s disease, being treated for 12 months will test cognition and use brain imaging to measure the effects of PBT2 on beta-amyloid deposits in the brain and effects on increasing brain activity.

In the interview, Dr. Zavoico added: “In preclinical studies, Prana’s lead drug candidate, PBT2, has been shown to redistribute zinc and other transition metals, preventing beta amyloid aggregation and even inducing its disaggregation. Sequestration of zinc in beta amyloid plaques reduces zinc levels inside the neuron, which can lead to its [tau protein’s] hyperphosphorylation. The metals hypothesis appears to unify the pathology underlying both amyloid plaque and neurofibrillary tangle formation, which makes this approach so compelling, in my mind”.

Notably, Huntington’s disease is also characterized by misfolding and aggregation of proteins, but of Huntingtin protein, not beta amyloid. Like Alzheimer’s, studies indicate that the pathology underlying Huntington’s disease is also due to abnormal distribution of certain transition metals. The Reach2HD trial, enrolling 100 patients with early to mid-stage Huntington’s disease, being treated for 6 months, aims to demonstrate safety, motor and behavioural benefits and the same cognitive benefits for Huntington’s patients that it has already demonstrated in Alzheimer’s patients treated with PBT2. Results of Prana’s clinical trials are expected in the second half of next year.

Prana’s CEO, Geoffrey Kempler, commented that “it is very encouraging that the strength of our science and the clinical potential of PBT2 is being recognized by industry experts and analysts, particularly at a time when so many competing drug candidates to treat Alzheimer’s have failed to meet their clinical endpoints. As some researchers are losing hope that Alzheimer’s can even be treated, we remain very confident in the potential of PBT2 to help patients”.

*The Life Sciences Report, A Streetwise Report, September 13, 2012.

About Prana Biotechnology Limited
Prana Biotechnology was established to commercialize research into age-related neurodegenerative disorders. The Company was incorporated in 1997 and listed on the Australian Securities Exchange in March 2000 and listed on NASDAQ in September 2002. Researchers at prominent international institutions including The University of Melbourne, The Mental Health Research Institute (Melbourne) and Massachusetts General Hospital, a teaching hospital of Harvard Medical School, contributed to the discovery of Prana’s technology.

For further information please visit the Company’s web site at www.pranabio.com.

Forward Looking Statements
This press release contains “forward-looking statements” within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934. The Company has tried to identify such forward-looking statements by use of such words as “expects,” “intends,” “hopes,” “anticipates,” “believes,” “could,” “may,” “evidences” and “estimates,” and other similar expressions, but these words are not the exclusive means of identifying such statements. Such statements include, but are not limited to any statements relating to the Company’s drug development program, including, but not limited to the initiation, progress and outcomes of clinical trials of the Company’s drug development program, including, but not limited to, PBT2, and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to the difficulties or delays in financing, development, testing, regulatory approval, production and marketing of the Company’s drug components, including, but not limited to, PBT2, the ability of the Company to procure additional future sources of financing, unexpected adverse side effects or inadequate therapeutic efficacy of the Company’s drug compounds, including, but not limited to, PBT2, that could slow or prevent products coming to market, the uncertainty of patent protection for the Company’s intellectual property or trade secrets, including, but not limited to, the intellectual property relating to PBT2, and other risks detailed from time to time in the filings the Company makes with Securities and Exchange Commission including its annual reports on Form 20-F and its reports on Form 6-K. Such statements are based on management’s current expectations, but actual results may differ materially due to various factions including those risks and uncertainties mentioned or referred to in this press release. Accordingly, you should not rely on those forward-looking statements as a prediction of actual future results.

Contacts:
Australia
Prana Biotechnology
+61 3 9349 4906

US
Leslie Wolf-Creutzfeldt
T: 646-284-9472
E: leslie.wolf-creutzfeldt@grayling.com

US – Media
Ivette Almeida
T: 646-284-9455

GlobalWise (GWIV) Channel Partner Sycle.net Delivers 148 New Installations

COLUMBUS, OH — (Marketwire) — 09/19/12 — GlobalWise Investments, Inc. (OTCBB: GWIV) (OTCQB: GWIV) (www.GlobalWiseInvestments.com) and its wholly owned subsidiary Intellinetics, Inc. (“Intellinetics”), a leading-edge technology company focused on the design, implementation and management of cloud-based Enterprise Content Management (“ECM”) systems in both the public and private sectors, today provide an update on the deployment of the co-developed eDocs platform with Sycle.net in audiology clinics.

Sycle.net is the hearing care industry’s number one provider for Enterprise Resource Planning (ERP) cloud-based software solutions. After an extensive due diligence process, Sycle.net chose Intellinetics as their ECM software partner. Together, both companies co-developed the private branded eDocs, a paperless office solution fully integrated within Sycle.net software, providing Sycle.net users the ability to easily organize important patient files within the easy-to-use Sycle.net interface.

Since the introduction of eDocs initially as a beta test with sixty users, Sycle.net and, as a result, GlobalWise, have on-boarded 148 new subscribers in the first 30 days of the official launch. There has been tremendous feedback from both new clients, as well as the sales force of Sycle.net, including how seamlessly the Intellivue™ software is integrated into the Sycle.net ERP audiology clinic software and how easy it is for clients to scan, sort and search for patient documents, especially within multiple offices where paper was previously stored on-site in filing cabinets.

“The addition of the Intellivue™ ECM software package to the rich Sycle.net ERP platform has been a tremendous success and one of the most successful ‘add-on’ releases in our history,” stated Ridge Sampson, President and CEO of Sycle.net. “There has been especially strong interest from multi-location clinics who in the past had difficulty sharing documents between locations. With the highly secure nature of the eDocs software, clients can access documents anywhere they have access to the internet, over a laptop, iPhone or iPad, making everyone more efficient at meeting patient needs.”

“I am extremely encouraged by the success of the integration and roll-out of the eDocs cloud-based offering with Sycle.net,” stated William J. “BJ” Santiago, CEO of GlobalWise. “Sycle.net dominates the audiology industry and services approximately 65% of the clinics nationwide, with over 5,800 audiology clinics and 18,000 users in place nationwide. The addition of Intellivue™ provides Sycle.net with a value-added/cloud-based service to sell to their clients in an easy and efficient manner. eDocs is a strong example of our Capture, Grow, and Harvest strategy in the market to drive rapid growth in our cloud subscriber user base.”

“The next phase for eDocs is potentially limitless,” continued Mr. Sampson. “Sycle.net is actively exploring deployment of eDocs in European markets through the joint globalization efforts of our software. This next year should be very exciting for both Sycle.net and GlobalWise.”

About GlobalWise Investments, Inc.

GlobalWise Investments, Inc., via its wholly owned subsidiary Intellinetics, Inc., is a Columbus, Ohio based Enterprise Content Management (ECM) pioneer with industry-leading software that delivers cloud ECM based solutions on-demand. The Company’s flagship platform, Intellivue™, represents a new industry benchmark and game-changing solution by enabling clients to access and manage the content of every scanned document, file, spreadsheet, email, photo, audio file or video tape — virtually anything that can be digitized — in their enterprise from any PC, laptop, tablet or smartphone from anywhere in the world.

For additional information, please visit the Company’s corporate website: www.GlobalWiseInvestments.com

This press release may contain “forward-looking statements.” Expressions of future goals and similar expressions reflecting something other than historical fact are intended to identify forward-looking statements, but are not the exclusive means of identifying such statements. These forward-looking statements may include, without limitation, statements about our market opportunity, strategies, competition, expected activities and expenditures as we pursue our business plan. Although we believe that the expectations reflected in any forward-looking statements are reasonable, we cannot predict the effect that market conditions, customer acceptance of products, regulatory issues, competitive factors, or other business circumstances and factors described in our filings with the Securities and Exchange Commission may have on our results. The company undertakes no obligation to revise or update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this press release.

GlobalWise Investments, Inc.
Columbus, Ohio
www.GlobalWiseInvestments.com
614-388-8909
Contact@GlobalWiseInvestments.com

Mission Investor Relations
Atlanta, Georgia
http://www.MissionIR.com
404-941-8975

SciClone (SCLN) Announces China Government-Mandated ZADAXIN Price Reduction

FOSTER CITY, CA — (Marketwire) — 09/18/12 — SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that consistent with the China government’s review of pharmaceutical prices once a product has been included into the Reimbursement Drug List (“RDL”), the retail list price, or hospital pharmacy level price, of ZADAXIN® has been reduced by about 18% in China. Based on agreements with SciClone’s primary importers of ZADAXIN into China to share the price reduction, the actual impact on SciClone’s revenue and margins is anticipated to be significantly lower than the percentage reduction at the retail level, and is expected to be less than a 5% decrease, with the importation and distribution network taking the majority of the percentage decrease.

As SciClone’s prior financial guidance for 2012 included an anticipated price reduction impact in the range of approximately 7-8%, the newly announced NDRC price and related agreements with importers will result in a more favorable outcome than previously anticipated. SciClone plans to address any impact of this less than 5% price decrease on the 2012 guidance when it announces third quarter 2012 financial results.

SciClone also announced that the NDRC price of Aggrastat®, a recently launched intervention cardiology product, as well as several of its oncology products exclusively promoted in China for Pfizer and Baxter were reduced at or below the average price reduction announced by the government.

It is noteworthy that ZADAXIN, Aggrastat and several of our oncology products continue to be independently listed, a substantial benefit in the tendering process allowing for preferential pricing compared to generics.

Commented Friedhelm Blobel, Ph.D., President and Chief Executive Officer of SciClone: “We respect the China government’s policy of price reviews of pharmaceuticals once listed in the RDL, and have anticipated for close to three years that a price reduction for ZADAXIN would be enacted. We are pleased that this review process has now been completed. We appreciate our importers’ agreement to assume the majority of the impact of the price reduction. Their actions reflect how highly ZADAXIN is valued by our industry partners and by patients with serious medical conditions who may now have greater access to this important and more affordable therapy.”

Continued Dr. Blobel: “We believe that this price revision can positively affect ZADAXIN sales through increased volume and broader penetration into tier 3 as well as tier 2 cities in target geographies, and that it can strengthen our provincial tendering strategies. We have more than 300 professionals wholly focused on building ZADAXIN sales. We are confident that ZADAXIN will continue to be a major growth engine for SciClone, fueled by successfully penetrating more deeply and widely into the China market on the national, provincial, city and institutional levels. We are also hopeful that with Aggrastat’s price now set, the provincial bidding and tender processes will proceed, and we can accelerate sales for this novel cardiology product, which has significant therapeutic potential in the fast-growing coronary stent market.”

ZADAXIN (thymalfasin) is approved in over 30 countries and may be used for the treatment of HBV, HCV, as a vaccine adjuvant, and certain cancers according to the approvals SciClone has in these countries. In China, thymalfasin is also included in the treatment guidelines issued by the Ministry of Health (“MOH”) for liver cancer. ZADAXIN was launched by SciClone in China in 1996, and was included as a Category B product in the RDL in 2009. In 2011, ZADAXIN annual worldwide sales exceeded $100 million. ZADAXIN has strong brand recognition, is positioned as a high-quality, imported product, and is one of the largest imported pharmaceutical products in China, measured by revenue. SciClone estimates its volume market share of thymalfasin is approximately 15%. SciClone believes that it has established a strong sales and marketing organization and strong importation relationships with distribution channels which have facilitated ZADAXIN’s strong growth in sales, profitability, and substantial cash flow. SciClone has built a strong commercial presence in liver disease, cancer and the intensive care setting, and is expanding geographically in China to position the Company for further growth.

About SciClone

SciClone Pharmaceuticals is a revenue-generating, profitable, specialty pharmaceutical company with a substantial commercial business in China and a product portfolio of therapies for oncology, infectious diseases and cardiovascular, urological, respiratory, and central nervous system disorders. SciClone’s ZADAXIN® (thymalfasin) is approved in over 30 countries and may be used for the treatment of hepatitis B (HBV), hepatitis C (HCV) and certain cancers, and as a vaccine adjuvant, according to the local regulatory approvals. Besides ZADAXIN, SciClone markets about 15 mostly partnered products in China, including Depakine®, the most widely prescribed broad-spectrum anti-convulsant in China; Tritace®, an ACE inhibitor for the treatment of hypertension; Stilnox®, a fast-acting hypnotic for the short-term treatment of insomnia (marketed as Ambien® in the US); and Aggrastat®, a recently-launched interventional cardiology product. SciClone is also pursuing the registration of several other therapeutic products in China. SciClone is headquartered in Foster City, California. For additional information, please visit www.sciclone.com.

Forward-Looking Statements

This press release contains forward-looking statements regarding expected financial results and expectations and the effect of the announced retail price reduction. Readers are urged to consider statements that include the words “may,” “will,” “would,” “could,” “should,” “might,” “believes,” “estimates,” “projects,” “potential,” “expects,” “plans,” “anticipates,” “intends,” “continues,” “forecast,” “designed,” “goal,” “unaudited,” “approximately” or the negative of those words or other comparable words to be uncertain and forward-looking. These statements are subject to risks and uncertainties that are difficult to predict and actual outcomes may differ materially. These include risk and uncertainties relating to: the course, cost and outcome of regulatory matters, including pricing decisions by authorities in China; the on-going regulatory investigations; the Company’s ability to execute on its goals in China and on its objectives for revenue in fiscal 2012; the challenges presented by integrating an acquired business into existing operations; the variability in earnings on a GAAP basis that may result from non-cash charges related to the NovaMed acquisition; the dependence on third party license, promotion or distribution agreements including the need to renew such agreements; operating an international business; the clinical trial process, including the regulatory approval and the process of initiating trials at, and enrolling patients at, clinical sites; the effect of changes in its practices and policies related to the Company’s compliance programs. SciClone cannot predict the timing or outcome of the SEC and DOJ investigations, or of the level of its efforts required to cooperate with those investigations, however the Company has incurred substantial expenses in connection with the investigations and related litigation and expects to incur additional expense and the investigations could result in fines and further changes in its internal control or other remediation measures that could adversely affect its business. Please also refer to other risks and uncertainties described in SciClone’s filings with the SEC. All forward-looking statements are based on information currently available to SciClone and SciClone assumes no obligation to update any such forward-looking statements.

Ambien, Depakine, Stilnox and Tritace are registered trademarks of Sanofi and/or its affiliates.

Aggrastat is a registered trademark of Medicure International Inc. in the United States, and Iroko Cardio LLC in numerous other countries.

SciClone, SciClone Pharmaceuticals, the SciClone Pharmaceuticals design, the SciClone logo and ZADAXIN are registered trademarks of SciClone Pharmaceuticals, Inc. in the United States and numerous other countries.

Corporate Contacts

Gary Titus
Chief Financial Officer
650.358.3456
gtitus@sciclone.com

Jane Green
Investors/Media
650.358.1447

Denison Mines Corp. (DNN) Comments on Recent Market Activity

TORONTO, ONTARIO — (Marketwire) — 09/18/12 — Denison Mines Corp. (“Denison” or the “Company”) (TSX:DML)(NYSE MKT:DNN)(NYSE Amex:DNN), in response to a request of the Investment Industry Regulatory Organization of Canada (IIROC) on behalf of the Toronto Stock Exchange, confirms that there are no material undisclosed corporate developments that might account for the increased trading activity of the Company’s shares today. Denison does not otherwise comment on market activity.

About Denison

Denison Mines Corp. is a uranium exploration and development company with interests in exploration and development projects in Saskatchewan, Zambia and Mongolia. As well, Denison has a 22.5% ownership interest in the McClean Lake uranium mill, located in northern Saskatchewan, which is one of the world’s largest uranium processing facilities. Denison’s exploration project portfolio includes the world-class Phoenix deposit located on its 60% owned Wheeler River project also in the Athabasca Basin region of Saskatchewan.

Denison is engaged in mine decommissioning and environmental services through its Denison Environmental Services (DES) division. Denison is also the manager of Uranium Participation Corporation (TSX-U), a publicly traded company which invests in uranium oxide in concentrates and uranium hexafluoride.

Cautionary Statements

Certain information contained in this press release constitutes “forward-looking information”, within the meaning of the United States Private Securities Litigation Reform Act of 1995 and similar Canadian legislation concerning the business, operations and financial performance and condition of Denison.

Generally, these forward-looking statements can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur”, “be achieved” or “has the potential to”.

Forward looking statements are based on the opinions and estimates of management as of the date such statements are made, and they are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Denison to be materially different from those expressed or implied by such forward-looking statements. Denison believes that the expectations reflected in this forward-looking information are reasonable but no assurance can be given that these expectations will prove to be correct and such forward-looking information included in this press release should not be unduly relied upon. This information speaks only as of the date of this press release. In particular, this press release may contain forward-looking information pertaining to the following: the estimates of Denison’s mineral resources; capital expenditure programs; estimated production costs, exploration and development expenditures and reclamation costs; expectations of market prices and costs; supply and demand for uranium; possible impacts of litigation and regulatory actions on Denison; exploration, development and expansion plans and objectives; Denison’s expectations regarding raising capital and adding to its mineral resources through acquisitions and development; and receipt of regulatory approvals, permits and licences and treatment under governmental regulatory regimes.

There can be no assurance that such statements will prove to be accurate, as Denison’s actual results and future events could differ materially from those anticipated in this forward-looking information as a result of those factors discussed in or referred to under the heading “Risk Factors” in Denison’s Annual Information Form dated March 28, 2012, available at http://www.sedar.com, and in its Form 40-F available at http://www.sec.gov, as well as the following: global financial conditions, the market price of Denison’s securities, volatility in market prices for uranium; ability to access capital, changes in foreign currency exchange rates and interest rates; liabilities inherent in mining operations; uncertainties associated with estimating mineral reserves and resources and production; uncertainty as to reclamation and decommissioning liabilities; failure to obtain industry partner and other third party consents and approvals, when required; delays in obtaining permits and licenses for development properties; competition for, among other things, capital, acquisitions of mineral reserves, undeveloped lands and skilled personnel; public resistance to the expansion of nuclear energy and uranium mining; uranium industry competition and international trade restrictions; incorrect assessments of the value of acquisitions; property title risk; geological, technical and processing problems; the ability of Denison to meet its obligations to its creditors; actions taken by regulatory authorities with respect to mining activities; the potential influence of or reliance upon its business partners, and the adequacy of insurance coverage.

Accordingly, readers should not place undue reliance on forward-looking statements. These factors are not, and should not be construed as being, exhaustive. Statements relating to “mineral reserves” or “mineral resources” are deemed to be forward-looking information, as they involve the implied assessment, based on certain estimates and assumptions that the mineral reserves and mineral resources described can be profitably produced in the future. The forward-looking information contained in this press release is expressly qualified by this cautionary statement. Denison does not undertake any obligation to publicly update or revise any forward-looking information after the date of this press release to conform such information to actual results or to changes in Denison’s expectations except as otherwise required by applicable legislation.

Cautionary Note to United States Investors Concerning Estimates of Measured, Indicated and Inferred Resources: This press release may use the terms “Measured”, “Indicated” and “Inferred” Resources. United States investors are advised that while such terms are recognized and required by Canadian regulations, the United States Securities and Exchange Commission does not recognize them. “Inferred Mineral Resources” have a great amount of uncertainty as to their existence, and as to their economic and legal feasibility. It cannot be assumed that all or any part of an Inferred Mineral Resource will ever be upgraded to a higher category. Under Canadian rules, estimates of Inferred Mineral Resources may not form the basis of feasibility or other economic studies. United States investors are cautioned not to assume that all or any part of Measured or Indicated Mineral Resources will ever be converted into Mineral Reserves. United States investors are also cautioned not to assume that all or any part of an Inferred Mineral Resource exists, or is economically or legally mineable.

Contacts:
Denison Mines Corp.
Ron Hochstein
President and Chief Executive Officer
(416) 979-1991 Extension 232

Denison Mines Corp.
James R. Anderson
Executive Vice President and Chief Financial Officer
(416) 979-1991 Extension 372

Misonix (MSON) Reports Strong Revenue Increases

Revenue Up 26.7% For Year Ended June 2012

Nuance to Acquire Ditech Networks (DITC)

Nuance Communications, Inc. (NASDAQ: NUAN) announced it has signed an agreement to acquire Ditech Networks, Inc. (NASDAQ: DITC). Ditech Networks’ voice technologies, including the company’s Voice Quality Assurance (VQA) technology and PhoneTag voicemail-to-text services, will further enhance Nuance’s portfolio of mobile and enterprise voice offerings.

As voice is increasingly integrated with a broad array of products and services, people expect seamless interactions that simply work anytime and anywhere. Ditech Networks’ portfolio of voice technologies will help Nuance continue its pace-setting innovations for carriers, consumers and enterprises across an array of products and services. In particular, Ditech Networks’ PhoneTag service will enhance Nuance’s Dragon Voice to Text Services business by adding important customers and complementary technologies, and further advance innovation supporting Nuance’s highly secure, on-premise voice to text platform.

“The world’s most innovative carriers and unified communications providers work with Nuance to take advantage of the revolution in voice recognition, and nowhere is this more evident than in our voicemail to text and call completion businesses, where billions of calls are converted into easily read text and email messages – a powerful solution for today’s messaging-centric world,” said John Pollard, Vice President and General Manager, Voice to Text Services, Nuance Mobile. “Acquiring Ditech Networks’ voice technologies will help Nuance continue to drive these next-generation services.”

Nuance has agreed to acquire Ditech Networks for $1.45 per share in cash, representing a total enterprise value of approximately $22.5 million, net of Ditech Networks’ cash as of the signing date. The transaction has been unanimously approved by the Boards of Directors of each company. The transaction is expected to close late in 2012, subject to Ditech Networks stockholder approval and other closing conditions.

“Ditech Networks’ voice technologies combined with Nuance’s voice and language understanding portfolio is an exciting proposition for our combined customer and partner base, while providing a unique opportunity to extend the value and benefits of our technologies into new markets,” said Ken Naumann, CEO, Ditech Networks.

About Ditech Networks

Ditech Networks provides advanced voice processing solutions that enable carriers, enterprises, and consumers to benefit from the power and simplicity of human speech. Ditech Networks is headquartered in San Jose, California. For more information, visit www.ditechnetworks.com.

About Nuance Communications, Inc.

Nuance is a leading provider of voice and language solutions for businesses and consumers around the world. Its technologies, applications and services make the user experience more compelling by transforming the way people interact with information and how they create, share and use documents. Every day, millions of users and thousands of businesses experience Nuance’s proven applications and professional services. For more information, please visit: nuance.com.

Additional Information and Where to Find It.

In connection with the proposed transaction, Ditech Networks will be filing documents with the SEC, including preliminary and definitive proxy statements relating to the proposed transaction. The definitive proxy statement will be mailed to Ditech Networks stockholders in connection with the proposed transaction. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE PRELIMINARY AND DEFINITIVE PROXY STATEMENTS WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION. Investors and security holders may obtain free copies of these documents (when they are available) and other related documents filed with the SEC at the SEC’s web site at www.sec.gov, on Ditech Networks’ website at www.ditechnetworks.com and by contacting Ditech Networks Investor Relations at (408) 883-3682.

Ditech Networks, Nuance and their respective directors and executive officers may be deemed participants in the solicitation of proxies from the stockholders of Ditech Networks in connection with the proposed transaction. Information regarding the special interests of Ditech Networks’ directors and executive officers in the proposed transaction will be included in the proxy statement described above. These documents are available free of charge at the SEC’s web site at www.sec.gov and from Ditech Networks Investor Relations as described above. Information about Nuance’s directors and executive officers can be found in Nuance’s definitive proxy statement filed with the SEC on December 15, 2011. You can obtain a free copy of this document at the SEC’s website at www.sec.gov or by accessing Nuance’s website at www.nuance.com and clicking on the “Investor Relations” link and then clicking on the “SEC Filings” link.

Nuance and the Nuance logo are trademarks or registered trademarks of Nuance Communications, Inc. or its subsidiaries in the United States of America and/or other countries. All other company names or product names may be the trademarks of their respective owners.

Statements in this press release regarding the anticipated closing date of the transaction between Nuance and Ditech Networks, the expected benefits to Nuance and its customers of the transaction, future product offerings by the combined company, and any other statements about Nuance managements’ future expectations, beliefs, goals, plans or prospects constitute forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words “will,” “expected,” and other similar expressions) should also be considered to be forward looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward looking statements, including: the transaction is subject to closing conditions that if not met or waived would cause the transaction not to close; the ability of Nuance to successfully integrate Ditech Networks’ operations, product offerings and employees; the ability to realize anticipated synergies and cost savings; the failure to retain customers and/or key employees; and the other factors described in Nuance’s Annual Report on Form 10-K for the fiscal year ended September 30, 2011, and other filings with the U.S. Securities and Exchange Commission. Ditech Networks and Nuance disclaim any intention or obligation to update any forward looking statements as a result of developments occurring after the date of this press release.

Duma Energy Corp. (DUMA) Zacks Initiating Coverage

Duma Energy Corp (OTC BB:DUMA) is an oil and natural gas company that owns producing properties in Texas and Illinois. The company has a significant interest is leases under exploration in Namibia that exceed 5 million acres with an estimated billion bbls of reserves in just one structure.

The company is profitable and revenue is growing rapidly. Our fiscal year 2013 (July 31) estimates are $20 million in revenue and $0.22 a share in earnings. Fiscal 2014 estimates are $34 million and $0.53 a share. The P/E on 2014 earnings is 3.6.

We are initiating coverage with an outperform rating and a $5 price target.

Please visit scr.zacks.com to access a free copy of the full research report.

SPAR Group (SGRP) Announces Acquisition of U.S. Merchandising Services Company

TARRYTOWN, NY — (Marketwire) — 09/17/12 — SPAR Group, Inc. (NASDAQ: SGRP) (the “Company” or “SPAR Group”), a leading supplier of retail merchandising and other marketing services throughout the United States and internationally, today announced that the company has acquired 51% of a U.S. based company that provides merchandising services to multiple Fortune 500 companies. The company is currently generating approximately $3 million in annual revenue specializing primarily on in-store merchandising and new store opening and remodeling projects.

“SPAR Group is pleased to announce the expansion of our domestic business,” said Gary Raymond, Chief Executive Officer of SPAR Group Inc. “This acquisition is part of management’s strategic plan to expand the overall scope of our U.S. based merchandising efforts in order to establish the company as the true market leader within the domestic retail merchandising industry. This acquisition, coupled with several additional U.S. opportunities, will allow us to strengthen our long-term competitive position in our targeted markets and enable us to service a broader range of retailers and manufacturers. We are pleased to tell our shareholders that this transaction combined with our recent international contract awards and newly announced Romania joint venture, place SPAR Group on a growth trajectory to achieve over $100 million in revenue going forward.”

About SPAR Group
SPAR Group, Inc. is a diversified international merchandising and marketing services Company and provides a broad array of services worldwide to help companies improve their sales, operating efficiency and profits at retail locations. The Company provides merchandising and other marketing services to manufacturers, distributors and retailers worldwide, primarily in mass merchandiser, office supply, grocery, drug, independent, convenience, electronics, toy and specialty stores, as well as providing furniture and other product assembly services, in-store events, radio frequency identification (“RFID”) services, technology services and marketing research. The Company has supplied these project and product services in the United States since certain of its predecessors were formed in 1979 and internationally since the Company acquired its first international subsidiary in Japan in May of 2001. Product services include restocking and adding new products, removing spoiled or outdated products, resetting categories “on the shelf” in accordance with client or store schematics, confirming and replacing shelf tags, setting new sale or promotional product displays and advertising, replenishing kiosks, providing in-store event staffing and providing assembly services in stores, homes and offices. Other merchandising services include whole store or departmental product sets or resets (including new store openings), new product launches, in-store demonstrations, special seasonal or promotional merchandising, focused product support and product recalls. The Company operates throughout the United States and internationally in 10 of the most populated countries, including China and India. For more information, visit the SPAR Group’s website at http://www.sparinc.com/.

Forward Looking Statements
Certain statements in this news release are forward-looking, including (without limitation) expectations or guidance respecting customer contract expansion, growing revenues and profits through organic growth and acquisitions, attracting new business that will increase SPAR Group’s revenues, continuing to maintain costs and consummating any transactions. Undue reliance should not be placed on such forward-looking statements because the matters they describe are subject to known and unknown risks, uncertainties and other unpredictable factors, many of which are beyond the Company’s control. The Company’s actual results, performance and trends could differ materially from those indicated or implied by such statements as a result of various factors, including (without limitation) the continued strengthening of SPAR Group’s selling and marketing functions, continued customer satisfaction and contract renewal, new product development, continued availability of capable dedicated personnel, continued cost management, the success of its international efforts, success and availability of acquisitions, availability of financing and other factors, as well as by factors applicable to most companies such as general economic, competitive and other business and civil conditions. Information regarding certain of those and other risk factors and cautionary statements that could affect future results, performance or trends are discussed in SPAR Group’s most recent annual report on Form 10-K, quarterly reports on Form 10-Q, and other filings made with the Securities and Exchange Commission from time to time. All of the Company’s forward-looking statements are expressly qualified by all such risk factors and other cautionary statements.

Contact:

James R. Segreto
Chief Financial Officer
SPAR Group, Inc.
(914) 332-4100

Investors:
Alan Sheinwald
Alliance Advisors, LLC
(212) 398-3486
Email Contact

Chris Camarra
Alliance Advisors, LLC
(212) 398-3487

Anthera Announces the Advancement of Blisibimod into Phase 3

HAYWARD, Calif., Sept. 17, 2012 /PRNewswire/ — Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation and autoimmune disorders, today provided an update on regulatory discussions for the global development of blisibimod.  End of Phase 2 discussions with the US Food and Drug Administration (FDA) have been completed and will allow for the submission of Phase 3 protocols and the initiation of registration studies.  Earlier in 2012, Anthera received a written response from the European Medicines Agency (EMA) providing similar development feedback for the blisibimod program.

“We appreciate the FDA’s rapid response to our development proposal for blisibimod. We will incorporate their comments and begin the initiation of our Phase 3 lupus program,” said Paul F. Truex, Anthera’s President and CEO.  “The PEARL-SC clinical study provided meaningful insight into the importance of selecting an appropriate patient population while also defining a meaningful endpoint.  We are grateful the FDA found this approach to be acceptable for further study and look forward to bringing blisibimod one step closer to patients in need.”

The Phase 3 studies (CHABLIS-SC1 and CHABLIS-SC2) will be multicenter, placebo-controlled, randomized, double-blind studies designed to evaluate the efficacy, safety, tolerability and immunogenicity of blisibimod in patients with clinically active SLE (SELENA-SLEDAI > 10) who have not achieved optimal resolution of their disease with corticosteroid use.  Patients will be treated in the controlled part of each study for 52 weeks after which they will have the option to receive additional treatment as part of an open-label, long-term, follow-up safety study. The primary endpoint of the CHABLIS studies will be a Systemic Lupus Erythematosus Response Index (SRI*) including the requirement of an eight-point or greater improvement from baseline in the SELENA/SLEDAI disease measurement (SRI-8).

“The use of an SRI-8 endpoint, in a population with higher baseline disease activity requires patients to demonstrate improvement in the clinical presentations of SLE, such as skin, mucosal, joint disease and kidney disease,” said Colin Hislop, Anthera’s Chief Medical Officer.  “For example, the blisibimod 200 mg weekly dose reduced proteinuria by nearly 1 gram per 24 hours at Week 24 compared with minimal change in the placebo group.  This corresponds to an approximate 50% decrease from baseline. These types of improvements were responsible for the majority of clinical benefits seen in the PEARL-SC study and highlights blisibimod’s potential to help patients with more active disease.”

As previously reported, results from the PEARL-SC study indicate that in the predefined population of patients with clinically active disease (SELENA-SLEDAI > 10) who were also taking corticosteroids, the SRI-8 treatment benefit in the 200 mg weekly blisibimod cohort was statistically significant at week eight (22.6% blisibimod response versus 6.4% placebo response, p=0.023) and at week 16 (35.4% blisibimod response versus 17.0% placebo response, p=0.04) through the 24 week endpoint (41.7% blisibimod response versus 10.4% placebo response, p<0.001). Results from the PEARL-SC clinical study have been submitted to the American College of Rheumatology for presentation at the ACR/ARHP Annual Scientific Meeting 2012 in Washington, D.C.

*SRI is defined as patients who respond to treatment and achieve a reduction in SELENA-SLEDAI equal to or greater than the number indicated, no new BILAG A or two B organ domain scores, and no increase in Physician’s Global Assessment (PGA) of greater than 0.3 on a three point scale.

About Anthera Pharmaceuticals

Anthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation and autoimmune diseases.

Safe Harbor Statement

Any statements contained in this press release that refer to future events or other non-historical matters, including statements that are preceded by, followed by, or that include such words as “estimate,” “intend,” “anticipate,” “believe,” “plan,” “goal,” “expect,” “project,” or similar statements, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on Anthera’s expectations as of the date of this press release and are subject to certain risks and uncertainties that could cause actual results to differ materially as set forth in Anthera’s public filings with the SEC, including Anthera’s Annual Report on Form 10-K for the year ended December 31, 2011 and Quarterly Report on Form 10-Q for the quarter ended June 30, 2012.  Anthera disclaims any intent or obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as required by applicable law.

CONTACT: Bianca Nery of Anthera Pharmaceuticals, Inc., bnery@anthera.com or 510.856.5586.

Timberline (TLR) Announces New Joint Venture Partner

COEUR D’ALENE, IDAHO — (Marketwire) — 09/17/12 — Timberline Resources Corporation (TSX VENTURE:TBR)(NYSE MKT:TLR)(NYSE Amex:TLR) (“Timberline” or the “Company”) announced today that its joint venture partner, Highland Mining, LLC (“Highland”) has sold its 50-percent interest in Butte Highlands JV, LLC (“BHJV”) to Montana State Gold Company, LLC (“MSGC”), a privately-owned Montana limited liability company. Highland will continue to be Timberline’s 50-percent joint venture partner at its Butte Highlands Gold Project, with MSGC funding development of the underground gold mine up to the commencement of commercial production. As a result of this sale, Timberline’s previously-announced non-binding letter of intent to acquire Highland’s interest in BHJV has terminated.

Timberline will continue to own a 50-percent carried-to-production interest in BHJV, as it has since the inception of the joint venture to develop Butte Highlands. MSGC has acquired Highland’s loan in the amount of approximately $24-million for development costs incurred at Butte Highlands to-date and will fund all remaining mine development costs through to commercial production. MSGC’s funding source is ISR Capital, a private investment and merchant-banking firm headquartered in Boise, Idaho. Both Timberline’s and MSGC’s shares of development costs, including the loan acquired by MSGC, will be repaid from proceeds of future mine production.

Paul Dircksen, Timberline’s Chief Executive Officer, said, “We are pleased to welcome MSGC as our partner at Butte Highlands. While we had earlier anticipated gaining 100-percent ownership of the project, Ron Guill’s decision to sell Highland Mining to a well-funded organization with a mandate to create jobs through commercial production provides Timberline and its shareholders with an attractive alternative. We now envision the achievement of production at Butte Highlands without assuming the development risk and without dilutive equity financing, burdensome debt financing, or the sale of valuable royalties that would have inevitably been required had we funded mine development ourselves. Rather, we are effectively in the same position as we were with Ron; we have a 50-percent carried-to-production interest at Butte Highlands while we advance our Lookout Mountain gold project in Nevada toward production.

Ron Guill, a Timberline Director, Timberline’s largest shareholder, and prior owner of Highland Mining, said, “I believe that this transaction is in the best interest of Timberline’s shareholders. We have created a new partnership that will fully fund the BHJV through the final permitting phase, the remaining development, and into commercial production. I have full confidence in the Timberline team to guide this project through the remaining steps and into full-scale gold production, and in the MSGC team who are committed to creating jobs by providing the necessary funding. I intend to remain involved as a significant investor and as an advisor and Director of Timberline.”

Mr. Dircksen continued, “Timberline has led the permitting efforts at Butte Highlands since early this year. While the details of an amended BHJV operating agreement with MSGC are still being worked out, we expect to maintain the momentum we have gained through frequent and productive discussions with the regulators by continuing to take the lead role in all permitting discussions, meetings, and activities until we receive our operating permit. We expect that we will receive the operating permit in mid-2013 and that gold production will commence soon after.”

As announced previously, the initial mine plan at Butte Highlands targets production of approximately 400 tons per day for the first four to five years of operation with the mineralized material expected to be direct shipped to a nearby mill, eliminating the immediate need to permit, finance and construct a mill. Development and permitting progress achieved at the project to-date includes:

--  Permitting complete for surface facilities construction, underground
    drilling and development, and a 10,000-ton bulk sample;
--  Production infrastructure and surface facilities are substantially
    complete;
--  Mine development is advanced, with more than 4,000 feet of underground
    workings complete;
--  50,000-foot underground drill program to support initial mine planning
    complete;
--  Water discharge (MPDES) permit application is complete and permit
    expected Q4 2012;
--  Haulage road special use permit in process and expected Q4 2012;
--  Hard Rock Operating Permit final amendments to be completed in Q3 2012
    with permit issuance expected in mid-2013;
--  Gold production expected to commence in mid-2013.

Butte Highlands is located approximately fifteen miles south of Butte, Montana within a favorable geologic domain that has hosted several world-class, multi-million ounce gold deposits including Butte, Golden Sunlight, Montana Tunnels, and Virginia City. The property was extensively drilled by Battle Mountain Gold, Placer Dome, ASARCO, and Orvana Minerals, prior to its acquisition by Timberline in 2006.

About Timberline Resources

Timberline Resources Corporation is exploring and developing advanced-stage gold properties in the western United States. Timberline holds a 50-percent carried interest ownership stake in the Butte Highlands Joint Venture in Montana where gold production is targeted to commence in mid-2013. Timberline’s exploration is primarily focused on the goldfields of Nevada, where it is advancing its flagship Lookout Mountain Project toward a production decision while exploring a pipeline of quality earlier-stage projects at its South Eureka Property and elsewhere. Timberline management has a proven track record of discovering economic mineral deposits and developing them into profitable mines.

Timberline is listed on the NYSE MKT where it trades under the symbol “TLR” and on the TSX Venture Exchange where it trades under the symbol “TBR”.

Forward-looking Statements

Statements contained herein that are not based upon current or historical fact are forward-looking in nature and constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such forward-looking statements reflect the Company’s expectations about its future operating results, performance and opportunities that involve substantial risks and uncertainties. These statements include but are not limited to statements regarding the timing of the Company’s permit applications and permit issuances, the Company’s continued exploration and drill program at South Eureka and Lookout Mountain, the timing of assay results from such drilling program being released, the Company’s ability to expand the South Eureka resource, the timing or results of the Company’s drill programs at Butte Highlands, including the timing of completing applications and obtaining necessary permits, the timing of the development and estimates of the timing of the commencement of production of gold at the Company’s Butte Highlands project and projects on its South Eureka property, the potential life of the mine at the Butte Highlands project, the targeted production date for the Butte Highlands project, targeted date for production at South Eureka, the potential for a heap-leach mine at South Eureka, targeted dates for the South Eureka technical report and economic scoping study, and possible growth of the Company and the Company’s expected operations, including potential development of an open pit extraction and run-of-mine heap leach processing and operation at South Eureka. When used herein, the words “anticipate,” “believe,” “estimate,” “upcoming,” “plan,” “target”, “intend” and “expect” and similar expressions, as they relate to Timberline Resources Corporation, its subsidiaries, or its management, are intended to identify such forward-looking statements. These forward-looking statements are based on information currently available to the Company and are subject to a number of risks, uncertainties, and other factors that could cause the Company’s actual results, performance, prospects, and opportunities to differ materially from those expressed in, or implied by, these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, risks related to the timing and completion of the drilling programs at Butte Highlands and South Eureka, risks and uncertainties related to mineral estimates, risks related to the inherently dangerous activity of mining, and other such factors, including risk factors discussed in the Company’s Annual Report on Form 10-K for the year ended September 30, 2011. Except as required by Federal Securities law, the Company does not undertake any obligation to release publicly any revisions to any forward-looking statements.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contacts:
Timberline Resources
Paul Dircksen
CEO
208.664.4859

ISR Capital
W. Kirk Williams
Corporate Counsel

Complete Genomics (GNOM) and BGI-Shenzhen Announce Definitive Agreement to Merge

Combination Will Create a Global Innovator in Whole Human Genomic Sequencing

MOUNTAIN VIEW, Calif. and SHENZHEN, China, Sept. 17, 2012 (GLOBE NEWSWIRE) — Complete Genomics, Inc. (Nasdaq:GNOM) (“Complete”), an innovative leader in whole human genomic sequencing, and BGI-Shenzhen (“BGI”), a leading international genomics company based in Shenzhen, China, today announced that they have entered into a definitive merger agreement. Through this agreement, a wholly-owned U.S. subsidiary of BGI will launch a tender offer to purchase all outstanding shares of common stock of Complete for $3.15 per share in cash, without interest. This price represents approximately a 54% premium to the $2.04 closing price per share of Complete common stock on June 4, 2012, the last trading day prior to Complete’s announcement that it was undertaking an evaluation of strategic alternatives to secure the financial resources needed for continued commercialization of its technology.

Complete’s board of directors has unanimously recommended that stockholders accept the offer and tender their shares. Based on the number of fully diluted outstanding shares of Complete, the aggregate value of the transaction is approximately $117.6 million. In addition, Complete and an affiliate of BGI have entered into an agreement pursuant to which Complete will be provided with up to $30 million in bridge financing for its operations following the signing of the merger agreement.

Complete provides whole human genome sequencing, which is used by research centers to conduct medical research that, in the future, is expected to be used by doctors and hospitals to improve both prevention and treatment of disease. BGI operates international genome sequencing centers, which support genetic research into agriculture, animals and humans and serve researchers around the world including the United States. The combination of the two companies is expected to bring together complementary scientific and technological expertise and R&D capabilities. Complete will continue to be operated as a separate company with headquarters and operations remaining in Mountain View, California.

BGI’s CEO Dr. Wang Jun said, “Complete has developed a proprietary whole human genome sequencing technology that, together with other sequencing platforms used by BGI, will fit well with our research and business requirements and position Complete to become an even more successful global innovator. We look forward to growing the business to improve medical research and, when clinical services are provided, support better disease diagnosis with tools that can be used by doctors and hospitals to treat their patients.”

“With the assistance of our advisors, we engaged in a thorough review of a broad set of possible alternatives for the company, and we believe the transaction with BGI represents the best outcome for our stockholders, offering them liquidity and a premium value,” said Dr. Clifford Reid, chairman and CEO of Complete. “In addition, it offers a great outcome for our customers, present and future. The combination of the companies’ resources provides an opportunity to accelerate our vision of providing researchers and physicians with the genomic information needed to prevent, diagnose, and treat cancers and other genetic diseases.”

The Offer and the Merger

Under the terms of the definitive merger agreement, a wholly-owned subsidiary of BGI will commence a tender offer to purchase all of the outstanding shares of Complete common stock for $3.15 per share in cash, without interest, within seven business days and the tender offer will remain open for a minimum of 20 business days following the commencement. All of Complete’s directors and executive officers as well as certain other major stockholders, who collectively own approximately 17.5% of the outstanding common stock of Complete, have entered into a tender and support agreement and have agreed to tender all of their shares pursuant to the tender offer. The tender offer is conditioned upon the satisfaction of various conditions, including, at least a majority of the outstanding common stock of Complete (determined on a fully diluted basis) being tendered, the termination of any waiting period under the U.S. Hart-Scott-Rodino Antitrust Improvements Act of 1976, clearance by the Committee on Foreign Investment in the United States, the approval of certain governmental authorities in the People’s Republic of China, as well as the satisfaction of other customary conditions. The transaction is expected to be completed in early 2013. The merger agreement also provides for the parties to effect, subject to customary conditions, a merger to be completed following the completion of the tender offer which would result in all shares not tendered in the tender offer being converted into the right to receive $3.15 per share in cash, without interest.

Advisors

Citi is serving as financial advisor for the transaction to BGI and O’Melveny & Myers LLP is acting as BGI’s legal counsel. Complete is advised by Jefferies & Company and its legal counsel is Latham & Watkins LLP.

About BGI

BGI includes both private non-profit genomic research institutes and sequencing application commercial units that provide comprehensive sequencing and bioinformatics services for medical, agricultural and environmental applications. Our commercial activities help our customers achieve their research goals by delivering rapid, high-quality results using a broad array of cost-effective, cutting-edge technologies. Our customers also benefit from our scientific expertise and research experience that have generated over 250 publications in top-tier journals such as Nature and Science. BGI is recognized globally as an innovator for conducting international collaborative projects with leading research institutions to better mankind and our world. Additional information about BGI and its U.S. subsidiary, BGI Americas, can be found at www.genomics.cn/en and www.bgiamericas.com.

About Complete

Through its pioneering sequencing-as-a-service model, Complete provides the most accurate whole human genome sequencing available today. The ease of use and power of Complete’s advanced informatics and analysis systems provide genomic information needed to better understand the prevention, diagnosis, and treatment of diseases. Additional information can be found at http://www.completegenomics.com.

Additional Information and Where to Find It

The tender offer proposed by a wholly-owned U.S. subsidiary of BGI referred to in this release has not yet commenced, and this release is neither an offer to purchase nor a solicitation of an offer to sell securities. If and when the tender offer is commenced, (i) BGI will cause to be filed with the Securities and Exchange Commission (the “SEC”) a tender offer statement and (ii) Complete Genomics, Inc. (the “Company”) will file with the SEC a Solicitation/Recommendation Statement on Schedule 14D-9. INVESTORS AND STOCKHOLDERS ARE URGED TO READ THE TENDER OFFER STATEMENT (INCLUDING AN OFFER TO PURCHASE, LETTER OF TRANSMITTAL AND RELATED TENDER OFFER DOCUMENTS) AND THE SOLICITATION/RECOMMENDATION STATEMENT ON SCHEDULE 14D-9 CAREFULLY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. Investors may obtain a free copy of these documents (if and when they become available) and other relevant documents filed with the SEC through the website maintained by the SEC at www.sec.gov. In addition, investors and stockholders will be able to obtain free copies of these materials filed by the Company by contacting Investor Relations by telephone at (650) 943-2788, by mail at Complete Genomics, Inc., Investor Relations, 2071 Stierlin Court, Mountain View, California 94043, or by going to the Company’s Investor Relations page on its corporate website at www.completegenomics.com.

Note on Forward-Looking Statements

Certain statements either contained in or incorporated by reference into this document are forward-looking statements that involve risks and uncertainty. Future events regarding the proposed transactions and both the Company’s and BGI’s actual results could differ materially from the forward-looking statements. Factors that might cause such a difference include, but are not limited to, statements regarding the combined companies’ plans following, and the expected completion of, the proposed acquisition. These forward-looking statements involve certain risks and uncertainties that could cause actual results to differ materially from those indicated in such forward-looking statements and generally include statements that are predictive in nature and depend upon or refer to future events or conditions. Risks and uncertainties include the ability of the Company and BGI to complete the transactions contemplated by the Merger Agreement, including the parties’ abilities to satisfy the conditions to the consummation of the proposed acquisition; the possibility of any termination of the merger agreement; the timing of the tender offer and the subsequent merger; uncertainties as to how many of the Company’s stockholders will tender their shares of common stock in the tender offer; the possibility that various other conditions to the consummation of the tender offer or the subsequent merger may not be satisfied or waived, including that a governmental entity may prohibit, delay or refuse to grant approval for the consummation of the acquisition; other uncertainties pertaining to the business of the Company or BGI; legislative and regulatory activity and oversight; the continuing global economic uncertainty and other risks detailed in the Company’s public filings with the SEC from time to time, including the Company’s most recent Annual Report on Form 10-K for the year ended December 31, 2012, Quarterly Reports on Form 10-Q and its subsequently filed SEC reports, each as filed with the SEC, which contains and identifies important factors that could cause actual results to differ materially from those contained in the forward-looking statements. The reader is cautioned not to unduly rely on these forward-looking statements. Each of the Company and BGI expressly disclaims any intent or obligation to update or revise publicly these forward-looking statements except as required by law.

CONTACT: MEDIA CONTACTS

         For Complete Genomics, Inc.:
         David Olmos
         Director of Editorial Strategies
         Waggener Edstrom Worldwide Healthcare
         Tel: (415) 547-7039
         Mobile: (323) 547-0572
         dolmos@waggeneredstrom.com

         For BGI-Shenzhen:
         In the U.S.
         Jason Golz
         Brunswick Group
         Tel: (415) 671-7676
         jgolz@brunswickgroup.com

         In China
         Martin Reidy
         Brunswick Group
         Tel: +86-10-5960-8600
         mreidy@brunswickgroup.com

ProPhase Labs (PRPH) Rejects Non-Binding Proposal to Be Acquired

ProPhase Labs Rejects Non-Binding Proposal to Be Acquired for $1.40 per Share From Matrixx Initiatives

DOYLESTOWN, PA — (Marketwire) — 09/17/12 — ProPhase Labs, Inc. (NASDAQ: PRPH) (www.ProPhaseLabs.com) announced today that it previously received an unsolicited, non-binding proposal from Matrixx Initiatives, Inc. (“Matrixx”) to acquire the Company for $1.40 per share in cash, subject to further due diligence by Matrixx. Matrixx is the owner of the Zicam® brand of cold and allergy products and is a direct competitor to ProPhase’s Cold-EEZE® Cold Remedy product line. Matrixx is controlled by H.I.G. Bayside Debt & LBO Fund II L.P., a private equity investment fund.

ProPhase first received a non-binding proposal to be acquired by a to-be-formed affiliate of Matrixx in a letter dated May 29, 2012. This proposal was unanimously rejected by the Company’s Board of Directors. Matrixx then repeated its non-binding proposal on the same terms in a letter to ProPhase dated September 6, 2012. Matrixx repeated the identical non-binding proposal in a September 14, 2012 letter. The Matrixx September 14 letter is attached to the report on Schedule 13D filed by Matrixx late on September 14.

On September 4, 2012, Matrixx purchased for $200,000 a three year option to acquire 1,453,427 shares of the Company’s common stock for $1.40 per share from Guy J. Quigley, ProPhase’s former Chairman and Chief Executive Officer. Matrixx also acquired from Mr. Quigley a voting proxy to vote the shares subject to the option. The Company learned of Matrixx’s transactions with Mr. Quigley through the filing by Mr. Quigley of reports on Form 4 and Form 13 D filed with the SEC.

In response to the May 29th proposal from Matrixx, the Company engaged independent financial advisors. At a meeting of the Board of Directors held on June 28, 2012, the Company’s Board of Directors, after careful consideration and consultation with its advisors, unanimously voted to reject the Matrixx proposal. Among other things, the Board unanimously determined, among other things, that:

• The non-binding Matrixx proposal undervalues ProPhase’s current business and future prospects.
• The Matrixx proposal does not adequately reflect the true value of ProPhase’s unique market position, business opportunities and new product launches. The Board believes that the Company’s recent and potential future revenue growth will result in superior value to that offered by Matrixx in a sale transaction.
• The Matrixx proposal is conditioned upon Matrixx being permitted access to non-public and confidential ProPhase information. Even if Matrixx were to sign a confidentiality agreement, there is undue risk to ProPhase in disclosing confidential information to one of its largest and most aggressive competitors.
• The interests of ProPhase’s stockholders will be best served by the Company continuing to pursue its independent strategic plan. The Company has made substantial investments in its Cold-EEZE® brand and believes that shareholders should be given the opportunity to realize a return on these investments.

Ted Karkus, Chairman and Chief Executive Officer of the Company stated:

“It is the current shareholders of ProPhase, not the private equity owners of one of our primary competitors, who should benefit from the future potential created by our current strategies.

We have successfully implemented a business and marketing strategy designed to deliver superior results to our stockholders over the long term. First, we preserved the Cold-EEZE® brand, then we repositioned the brand, and now we are successfully growing and leveraging the brand. As we have consistently explained to our shareholders, it remains our view that by investing in our Cold-EEZE® brand, we are building our distribution platform and pipeline, which has led to securing increased shelf space with our retailers for the upcoming cold season, and which has provided us with the opportunity to introduce new and improved products, including the national launch of Cold-EEZE® Oral Spray and Cold-EEZE® Daytime/Nighttime QuickMelts® for the upcoming cold season.”

Mr. Karkus added:

“During 2011 and 2012, our revenues have been increasing while at the same time, based on available industry data, many competing cough/cold products in our category are experiencing notable declines in year over year sales. Therefore, we are not surprised, and in fact flattered, that our most significant cough/cold competitor recognizes our success to date, intrinsic value and future potential that current management has created, by suggesting that they acquire ProPhase.”

About ProPhase Labs

ProPhase Labs is a diversified natural health medical science company. It is a leading marketer of the Cold-EEZE® Cold Remedy brand as well as other cold relief products. Cold-EEZE® zinc gluconate lozenges are clinically proven to significantly reduce the severity and duration of the common cold. Cold-EEZE® customers include leading national retailers, chain food, drug and mass merchandise stores, wholesalers and distributors, as well as independent pharmacies. ProPhase Labs has several wholly owned subsidiaries including a manufacturing unit, which consists of an FDA registered facility to manufacture Cold-EEZE® lozenges and fulfill other contract manufacturing opportunities. ProPhase also owns 50% of Phusion Laboratories, LLC (“Phusion”). Phusion licenses a revolutionary proprietary technology that has the potential to improve the delivery and/or efficacy of many active ingredients or compounds. Phusion will formulate and test products to exploit market opportunities within ProPhase’s robust over-the-counter distribution channels. For more information visit us at www.ProPhaseLabs.com.

Forward Looking Information

Except for the historical information contained herein, this document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks and uncertainties, including the difficulty of the acceptance and demand for our products, the impact of competitive products and pricing, the timely development and launch of new products, and the risk factors listed from time to time in our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and any subsequent SEC filings.

Press Only Contact
Jenny Miranda
5W Public Relations
Tel: (212) 584-4295
jmiranda@5wpr.com

Investor Contact
Ted Karkus
Chairman and CEO
ProPhase Labs, Inc.

Celsion (CLSN) Phase III HEAT Study of ThermoDox in Primary Liver Cancer

Celsion Announces Independent Data Monitoring Committee Completes Last Intermediate Review of Phase III HEAT Study of ThermoDox(R) in Primary Liver Cancer Prior to Final Data
http://media.marketwire.com/attachments/201103/46158_CLSN.JPGhttp://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=930399&ProfileId=051205&sourceType=1

LAWRENCEVILLE, NJ — (Marketwire) — 09/14/12 — Celsion Corporation (NASDAQ: CLSN), a leading oncology drug development company, today announced that the independent Data Monitoring Committee (DMC) for the Company’s HEAT Study, a fully enrolled, multinational, double-blind, placebo-controlled, pivotal Phase III trial of ThermoDox® in combination with radiofrequency ablation (RFA) for hepatocellular carcinoma (HCC or primary liver cancer), has completed a regularly scheduled review of all 701 patients enrolled in the trial and has unanimously recommended that the HEAT Study continue according to protocol to its final data readout. The HEAT Study is being conducted under a Special Protocol Assessment (SPA) agreed to with the U.S. Food and Drug Administration (FDA).

The primary endpoint for the HEAT Study, progression-free survival (PFS), is defined in the SPA. A total of 380 PFS events are required to reach the unblinding and planned final analysis of the study. Celsion reconfirmed that 380 PFS events are projected to occur in the fourth quarter of 2012, with top line results announced following DMC review and confirmation.

The DMC has reviewed study data at regular intervals, with the primary responsibilities of ensuring the safety of all patients enrolled in the study, the quality of the data collected, and the continued scientific validity of the study design. As part of its review of all 701 patients, the DMC monitored a quality matrix relating to the total clinical data set, confirming the timely collection of data, that all data are current as well as other data collection and quality criteria.

“We sincerely thank the DMC for their diligent work in ensuring the quality and consistency of data from all 701 patients in the HEAT Study, as we approach the announcement of top line results,” said Michael H. Tardugno, Celsion’s President and Chief Executive Officer. “The HEAT Study is the single largest study ever conducted in intermediate-stage primary liver cancer, the largest unaddressed cancer in oncology today. Celsion is well prepared for the outcome of the HEAT Study, with the regulatory, manufacturing, financial and commercial plans and resources in place to ensure success. We look forward to the next steps for ThermoDox® and remain confident in its potential to provide a new and important therapeutic option for patients with this disease.”

The HEAT Study, in addition to being conducted under an FDA Special Protocol Assessment, has received FDA Fast Track Designation and has been designated as a Priority Trial for liver cancer by the National Institutes of Health. ThermoDox® has been granted orphan drug designation in both the U.S. and Europe. The European Medicines Agency (EMA) has confirmed the HEAT Study provides an acceptable basis for submission of a marketing authorization application (MAA) for centralized review and approval. In addition to meeting the U.S. FDA and European EMA enrollment objectives, the HEAT Study has also enrolled a sufficient number of patients to support registrational filings in China, South Korea and Taiwan, three other large and important markets for ThermoDox®.

About Primary Liver Cancer

Primary liver cancer is one of the most deadly forms of cancer and ranks as the fifth most common solid tumor cancer. The incidence of primary liver cancer today is approximately 26,000 cases per year in the United States, approximately 40,000 cases per year in Europe and is rapidly growing worldwide at approximately 750,000 cases per year, 55 percent of which are in China, due to the high prevalence of Hepatitis B and C in developing countries. The World Health Organization estimates that primary liver cancer may become the number one cancer worldwide, surpassing lung cancer, by 2020.

About ThermoDox® and the Phase III HEAT Study

ThermoDox® is a proprietary heat-activated liposomal encapsulation of doxorubicin, an approved and frequently used oncology drug for the treatment of a wide range of cancers. In the HEAT Study, ThermoDox® is administered intravenously in combination with Radio Frequency Ablation (RFA). Localized mild hyperthermia (39.5 – 42 degrees Celsius) created by the RFA releases the entrapped doxorubicin from the liposome. This delivery technology enables high concentrations of doxorubicin to be deposited preferentially in a targeted tumor.

For primary liver cancer, ThermoDox® is being evaluated in a global, multi-center, randomized, pivotal Phase III HEAT Study at 79 clinical sites under an FDA Special Protocol Assessment. The study is designed to evaluate the efficacy of ThermoDox® in combination with RFA when compared to patients who receive RFA alone as the control. The primary endpoint for the study is progression-free survival with a secondary confirmatory endpoint of overall survival. Additional information on the Company’s ThermoDox® clinical studies may be found at www.clinicaltrials.gov.

About Celsion Corporation

Celsion is a leading oncology company dedicated to the development and commercialization of innovative cancer drugs including tumor-targeting treatments using focused heat energy in combination with heat-activated liposomal drug technology. Celsion has research, license, or commercialization agreements with leading institutions including the National Institutes of Health, Duke University Medical Center, University of Hong Kong, the University of Pisa, the UCLA Department of Medicine, the Kyungpook National University Hospital, the Beijing Cancer Hospital and the University of Oxford.

For more information on Celsion, visit our website: http://www.celsion.com.

Celsion wishes to inform readers that forward-looking statements in this release are made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, unforeseen changes in the course of research and development activities and in clinical trials by others; possible acquisitions of other technologies, assets or businesses; possible actions by customers, suppliers, competitors, regulatory authorities; and other risks detailed from time to time in the Company’s periodic reports filed with the Securities and Exchange Commission.

Celsion Investor Contact
David Pitts
Argot Partners
212-600-1902
Email Contact

Golden Star Resources (GSS) Redeems $6.13 Million of 4% Convertible Senior Unsecured Debentures

DENVER, CO–(Marketwire – September 14, 2012) – Golden Star Resources Ltd. (NYSE MKT: GSS) (TSX: GSC) (GHANA: GSR) (“Golden Star” or the “Company”) today announced that it has redeemed $6.13 million of its 4.00% Convertible Senior Unsecured Debentures due November 30, 2012, (the “Original Debentures”) by way of a privately negotiated transaction initiated by a certain holder of Original Debentures. All references to “$” in this press release are to United States dollars.

After purchasing and cancelling the $6.13 million of Original Debentures, an aggregate of $44.37 million principal amount of Original Debentures remains outstanding. As previously disclosed, the Company’s current financial plan is to pay the outstanding principal of the remaining Original Debentures plus accrued interest in cash.

COMPANY PROFILE

Golden Star Resources holds the largest land package in one of the world’s largest and most prolific gold producing regions. The Company holds a 90% equity interest in Golden Star (Bogoso/Prestea) Limited and Golden Star (Wassa) Limited, which respectively own the Bogoso/Prestea and Wassa/HBB open-pit gold mines in Ghana, West Africa. In addition, Golden Star has an 81% interest in the currently inactive Prestea Underground mine in Ghana, as well as gold exploration interests elsewhere in Ghana, in other parts of West Africa and in Brazil in South America. Golden Star has approximately 259 million shares outstanding. Additional information is available at www.gsr.com.

This announcement does not constitute an offer to sell, nor is it a solicitation of an offer to sell, securities.

Statements Regarding Forward-Looking Information: Some statements contained in this news release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other applicable securities laws. Investors are cautioned that forward-looking statements are inherently uncertain and involve risks and uncertainties that could cause actual results to differ materially, including comments regarding the expectation that the Company will redeem the remaining $44.37 million of Original Debentures in cash and other statements that express management’s expectations or estimates of future developments, circumstances or results. Actual results may differ materially from those presented. Factors that could cause results to differ materially include fluctuations in gold price, disruptions in U.S. and Canadian securities markets, and other factors that may cause actual results, performance or achievements to be materially different from those expressed or implied. Golden Star assumes no obligation to update this information. Please refer to the discussion of risk factors in our Form 10-K for the year ended December 31, 2011.

Facebook and Zynga (ZNGA) Shares Rally on Comments From Zuckerberg

NEW YORK, NY — (Marketwire) — 09/14/12 — Mobile advertising has been a major focus for the Social Media Industry as companies look to profit from the rapidly rising demand for mobile devices. According to data from StatCounter Inc. mobile devices represent more than 10 percent of all internet traffic, a sharp increase from the 4 percent in January 2011. The Paragon Report examines investing opportunities in the Social Media Industry and provides equity research on Facebook Inc. (NASDAQ: FB) and Zynga Inc. (NASDAQ: ZNGA).

Access to the full company reports can be found at:

www.ParagonReport.com/FB
www.ParagonReport.com/ZNGA

Digital marketing and media research firm eMarketer predicts that U.S. mobile advertising revenues will experience rapid growth in the coming years. The research group has projected that U.S. mobile advertising revenues to more than quadruple from the $1.45 billion seen in 2011 to $6.62 billion in 2014, and to be worth nearly $12 billion by 2016. According to eMarketer Twitter CEO Dick Costolo has stated that “on most days” more ad revenues are generated through mobile platforms than their website.

Paragon Report releases regular market updates on the Social Media Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.ParagonReport.com and get exclusive access to our numerous stock reports and industry newsletters.

Shares of Facebook surged nearly 8 percent Wednesday after comments made by CEO Mark Zuckerberg at recent conference provided a positive outlook. “Now we are a mobile company,” said Zuckerberg. “Over the next three to five years I think the biggest question that is on everyone’s minds, that will determine our performance over that period, is really how well we do with mobile.”

Shares of Zynga also received a boost Wednesday gaining over 10 percent after Zuckerberg gave the company a positive endorsement. “Zynga’s had a rough few quarters. They’re basically a strong company,” he said, according to recent AllThingsD article. “Other companies, like King.com and Kixeye, have gained share. We have 200 million people playing games monthly. That’s real.”

The Paragon Report has not been compensated by any of the above-mentioned publicly traded companies. Paragon Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at: http://www.paragonreport.com/disclaimer

Sutor Technology Group (SUTR) Limited Reports Fiscal Year 2012 Financial Results

Virco (VIRC) Announces Second Quarter Results

TORRANCE, Calif., Sept. 14, 2012 (GLOBE NEWSWIRE) — Virco Mfg. Corporation (Nasdaq:VIRC) today announced second quarter results in the following letter to stockholders from Robert A. Virtue, President and CEO:

While our second quarter revenues continue to reflect an uneven recovery in state and municipal funding for public schools, last year’s restructuring led to significantly improved financial results for the second quarter and first half of fiscal 2012 compared to the same periods in fiscal 2011.

Revenues for the second quarter declined 3.9% from $62,817,000 in the three months ended July 31, 2011 to $60,392,000 in the three months ended July 31, 2012. Revenues for the first half of the year declined 3.5% from $87,073,000 in the first six months ended July 31, 2011 to $84,060,000 for the first six months ended July 31, 2012. Despite these modest revenue declines, net operating efficiencies resulted in significantly improved financial results. Gross profit for the second quarter was up 15.0% from $19,882,000 in the three months ended July 31, 2011 to $22,867,000 in the three months ended July 31, 2012, while expenses were down 9%, from $17,107,000 in the three months ended July 31, 2011 to $15,608,000 in the three months ended July 31, 2012. For the first six months, gross profit was up 11.9% from $26,660,000 in the first six months ended July 31, 2011 to $29,834,000 in the first six months ended July 31, 2012. Expenses were down 6.4% from $29,257,000 in the first six months ended July 31, 2011 to $27,392,000 in the first six months ended July 31, 2012.

As a result of the improvement in net operating efficiencies, net income more than doubled (up 257%) from $2,732,000 in the three months ended July 31, 2011 to $7,053,000 in the three months ended July 31, 2012. Through six months ended July 31, 2012, we’ve earned net income of $2,220,000 compared to last year’s net loss of $2,668,000 for the six months ended July 31, 2011.

Here are our results for the second quarter and six months ended July 31, 2012, and the comparable periods last year:
Three Months Ended Six Months Ended
7/31/2012 7/31/2011 7/31/2012 7/31/2011
(In thousands, except share data)

Net sales $60,392 $62,817 $84,060 $87,073
Cost of sales 37,525 42,935 54,226 60,413
Gross profit 22,867 19,882 29,834 26,660
Selling, general administrative & other expense 15,608 17,107 27,392 29,257
Income (loss) before income taxes 7,259 2,775 2,442 (2,597)
Income tax expense 206 43 222 71
Net income (loss) $7,053 $2,732 $2,220 ($2,668)

Net income (loss) per share – basic (a) $0.49 $0.19 $0.15 ($0.19)

Weighted average shares outstanding – basic (a) 14,369 14,274 14,333 14,240
Weighted average shares outstanding – diluted 14,395 14,292 14,358 14,240

(a) Net loss per share was calculated based on basic shares outstanding due to the anti-dilutive effect on the inclusion of common stock equivalent shares.
7/31/2012 1/31/2012 7/31/2011
Current assets $75,837 $45,808 $82,024
Non-current assets 46,810 48,417 49,802
Current liabilities 52,331 26,840 60,362
Non-current liabilities 36,870 36,489 24,202
Stockholders’ equity 33,446 30,896 47,262

As discussed more fully in our Annual Report on Form 10-K for fiscal 2011 (year ended January 31, 2012), last year we implemented a voluntary early retirement program to bring our cost structure back in line with revenues. When combined with normal attrition, this resulted in a 21% reduction in total headcount as we entered fiscal 2012. The reductions were primarily concentrated in manufacturing, and included both direct labor and indirect support positions.

This reduction in staffing supported a planned reduction in total inventories. At the end of the first quarter of this year, inventories were 22% lower than at the same date last year. However, because incoming orders were roughly even with the prior year, this meant that our factories had to be highly productive and flexible to meet the delivery dates and product mix of our second quarter backlog. It was a significant challenge, but our operations teams performed very well.

Using a combination of automation, overtime and temporary labor, factory output increased 18% in the second quarter of fiscal 2011, enabling us to simultaneously satisfy customer demand, maintain inventory discipline and cut operating expenses. At the end of July 2012, total inventories were $37,684,000 compared to $43,509,000 last year, a reduction of 13%.

During the current year, we have been operating in an environment of relatively stable commodity costs. Last year’s results were adversely affected by 25% spikes in two of our most important raw materials—steel and plastic resin—at the beginning of the second quarter of fiscal 2011. This year’s more stable costs have enabled us to retain the financial benefits of last year’s restructuring. The difference is most visible in the net income comparison for the second quarter, which bears the full weight of our seasonal business cycle.

During the last decade, many other manufacturers moved their operations offshore in an effort to reduce product costs. Over this same period, we elected instead to invest in automation, new products, and new service technologies rather than closing our domestic factories. We believe this approach may finally be yielding the financial performance benefits originally envisioned. Specifically, the shorter, better controlled supply chains of our own domestic factories allow us to offer a wider range of product choices with shorter lead times to support the rapidly-evolving environments of 21st Century campuses and classrooms. This responsiveness is further supported by our own direct sales and service force, which isn’t constrained by the short-term concerns and multiple linkages of extended supply chain/distribution models.

Our commitment to produce and deliver outstanding furniture and equipment starts with quality raw materials and includes rigorous regulatory compliance, careful craftsmanship, and dependable warranties. Manufacturers with extended supply chains can be tempted to point the finger and blame shortcomings on one or more links in the chain. At Virco, we take direct responsibility for our own tangible products as well as the less tangible but essential follow-through services.

Labor Day is the traditional end of our summer delivery season. In the four months of June though September, we usually ship more than half our total annual revenue. As this report was being written we had concluded a successful August that mirrored the improvements of the second quarter. Although we won’t report officially on August until our third quarter report in December 2012, it seems appropriate during this crucial turnaround year to give stockholders a sense of how the summer’s results influence our thinking about the future.

First, we caution that publicly-funded entities continue to suffer serious budget challenges. Reduced tax revenues and structural spending deficits have proven difficult to correct, with the result that many of our largest and most stable public school customers have been forced to reduce their day-to-day expenditures for replacement furniture. As noted in several of our recent Annual Reports, this reduction has been partially offset by highly localized pockets of strength in bond-funded new school construction and the international sector. Despite these shifts in composition, our order rates through late summer 2012 have remained roughly even with order rates over the same period in 2011. We certainly hope this stability will persist through fiscal 2012, but given the many uncertainties of public funding, we can’t guarantee it.

Second, this year’s stable raw material costs may not be permanent. Along with increased volatility in our own order cycle, the last few years have been marked by unusual volatility in the cost (and supply) of raw materials. Whether or not this volatility was a consequence of the uneven balancing-out of the global supply chain, or whether it’s the ‘new normal,’ we can’t say.

Third, the restructuring expenses in last year’s third and fourth quarters won’t be repeated this year. We therefore believe our year-to-date operating efficiencies as reflected in the first half results should now be relatively fixed. We remind stockholders, however, that due to the intense seasonality of our business, the lower revenues in our first and fourth quarters typically generate operating losses for those periods, so straight-line extrapolations of year-to-date results may be misleading.

Given these cautions, we believe we are well positioned for the foreseeable future. As the risk of extended supply chains become more evident to suppliers and customers alike, our modern but almost-fully-depreciated domestic factories seem likely to offer consistent advantages in quality, choice, and reliability. We intend to emphasize and profit from these advantages as we work with educators to equip the learning environments of the future.

The Virco Mfg. Corporation Logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=521

This news release contains “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding: business strategies; market demand and product development; economic conditions; the educational furniture industry; international markets; product sourcing; raw material costs; state and municipal bond funding; order rates; operating efficiencies; supply chains; the Company’s domestic factors; and seasonality. Forward-looking statements are based on current expectations and beliefs about future events or circumstances, and you should not place undue reliance on these statements. Such statements involve known and unknown risks, uncertainties, assumptions and other factors, many of which are out of our control and difficult to forecast. These factors may cause actual results to differ materially from those which are anticipated. Such factors include, but are not limited to: changes in general economic conditions including raw material, energy and freight costs; state and municipal bond funding; state, local and municipal tax receipts; the seasonality of our markets; the markets for school and office furniture generally; the specific markets and customers with which we conduct our principal business; and the competitive landscape, including responses of our competitors to changes in our prices. See our Annual Report on Form 10-K for the year ended January 31, 2012, and other materials filed with the Securities and Exchange Commission for a further description of these and other risks and uncertainties applicable to our business. We assume no, and hereby disclaim any, obligation to update any of our forward-looking statements. We nonetheless reserve the right to make such updates from time to time by press release, periodic reports or other methods of public disclosure without the need for specific reference to this press release. No such update shall be deemed to indicate that other statements which are not addressed by such an update remain correct or create an obligation to provide any other updates.

CONTACT: Robert A. Virtue, President
Douglas A. Virtue, Executive Vice President
Robert E. Dose, Vice President Finance
Virco Mfg. Corporation
(310) 533-0474

FriendFinder Networks (FFN) Continues To Successfully Optimize Business

FriendFinder Networks Continues To Successfully Optimize Business Resulting In Adjusted EBITDA Of $8.0 Million For July 2012

SUNNYVALE, Calif., Sept. 13, 2012 /PRNewswire/ — FriendFinder Networks Inc. (NasdaqGM: FFN) (the “Company”), a leading internet and technology company providing services in the rapidly expanding markets of social networking and web-based video sharing, today announced improved operating results.

“As highlighted in our recent second quarter earnings release and conference call, FriendFinder Networks has undertaken an aggressive effort to optimize our business and streamline our cost structure. In doing so, we have redirected our efforts to foster stronger growth in our core network of brands,” said Anthony Previte, Chief Executive Officer of FriendFinder Networks. “The overarching goals are to improve new subscriber conversion rates and to reduce churn and customer acquisition costs. For the month of July 2012, these efforts resulted in significant operational improvements, including strong adjusted EBITDA.”

Non-GAAP Financial Measures

Management believes that certain non-GAAP financial measures of earnings before deducting net interest expense, income taxes, depreciation and amortization, or EBITDA, and Adjusted EBITDA are helpful financial measures as investors, analysts and others frequently use EBITDA and Adjusted EBITDA in the evaluation of other companies in FriendFinder Networks Inc.’s industry.

These non-GAAP financial measures may not provide information that is directly comparable to that provided by other companies in FriendFinder Networks Inc.’s industry, as other companies in FriendFinder Networks Inc.’s industry may calculate such financial measures differently, particularly as it relates to nonrecurring, unusual items. The Company’s non-GAAP financial measures of EBITDA and Adjusted EBITDA are not measurements of financial performance under GAAP and should not be considered as alternatives to cash flow from operating activities or as measures of liquidity or as alternatives to net income or as indications of operating performance or any other measure of performance derived in accordance with GAAP.

Management derived EBITDA and Adjusted EBITDA for the month ended July 31, 2012 using the adjustments shown in the attached reconciliation table.

SAFE HARBOR

This press release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Actual results may differ from expectations, estimates and projections and, consequently, you should not rely on these forward looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results.

Additional information concerning these and other risk factors is contained in the Company’s most recent filings with the SEC, including its Form 10-K for the year ended December 31, 2011. All subsequent written and oral forward-looking statements concerning the Company are expressly qualified in their entirety by the cautionary statements above and subject to such risk factors discussed in the Company’s recent SEC filings. The Company cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statement to reflect any change in their expectations or any change in events, conditions or circumstances on which any such statement is based.

ABOUT FRIENDFINDER NETWORKS INC.

FriendFinder Networks Inc. (www.FFN.com) is an internet-based social networking and technology company operating several of the most heavily visited websites in the world, including AdultFriendFinder.com, Amigos.com, AsiaFriendFinder.com, Cams.com, FriendFinder.com, BigChurch.com and SeniorFriendFinder.com. FriendFinder Networks Inc. also produces and distributes original pictorial and video content and engages in brand licensing.

Investor Contact for FriendFinder Networks Inc.
Jeffrey Goldberger / Rob Fink
KCSA Strategic Communications
212.896.1206 or jgoldberger@kcsa.com / rfink@kcsa.com

Media Contact for FriendFinder Networks Inc.
Lindsay Trivento
Director, Corporate Communications
561.912.7010 or ltrivento@ffn.com

Reconciliation of GAAP Net Income to EBITDA and Adjusted EBITDA

Month Ended

July 31, 2012

(Unaudited)

(in thousands)

GAAP net income

$

1,083

Add: Interest expense, net

7,109

Subtract/Add: Income tax (benefit)/expense

–

Add: Amortization of acquired intangible assets and software

1,244

Add: Depreciation and other amortization

255

EBITDA

$

9,691

Subtract/Add: (Gain)/Loss related to VAT liability not charged to customers

(1,809)

Add: Discontinued Operations

116

Adjusted EBITDA

$

7,998

Response Genetics (RGDX) Raises $8.8 Million in Financing

Response Genetics Raises $8.8 Million in Financing
Company to Present at UBS Global Life Sciences in NYC on September 20, 2012

LOS ANGELES, Sept. 13, 2012 /PRNewswire/ — Response Genetics, Inc. (Nasdaq: RGDX) announced today that it has entered into a purchase agreement with GlaxoSmithKline and one of its existing significant stockholders to raise $8.8 million from the private placement of 8,000,000 newly issued shares of its common stock at a purchase price of $1.10 per share.

The signing of the purchase agreement and closing of the financing occurred today, Thursday, September 13, 2012.

“We are pleased to welcome GlaxoSmithKline as a new investor, given our long standing relationship,” said Thomas Bologna, chairman and chief executive officer of Response Genetics, Inc. “The capital raised will help support our continued efforts in building a sustainable business of high value genetic tests for cancer patients as well as a premier pharmaceutical services business. Going forward we will continue to implement additional operational efficiencies, as evidenced by our improved financial performance relative to the fourth and subsequent quarters of last year, and will also increase our focus and efforts on growing top line revenue.”

The securities sold in the private placement have not been registered under the Securities Act of 1933, as amended, or state securities laws and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission (“SEC”) or an applicable exemption from the registration requirements. Response Genetics, Inc. has agreed to file a registration statement with the SEC covering the resale of the shares of common stock issued in the private placement. This press release shall not constitute an offer to sell or the solicitation of an offer to buy Response Genetics, Inc.’s common stock.

Thomas A. Bologna, Response Genetic’s chairman & chief executive officer, will present at the UBS 2012 Global Life Sciences Conference taking place at the Grand Hyatt in New York City on Thursday, September 20, 2012 at 11:00 a.m. ET.

Interested investors can access a live webcast of the presentation by going to the Investor Relations tab on the Response Genetics website: www.responsegenetics.com. A replay of the webcast will be made available on the company’s website for 60 days.

About Response Genetics, Inc.

Response Genetics, Inc. (the “Company”) is a CLIA-certified clinical laboratory focused on the development and sale of molecular diagnostic testing services for cancer. The Company’s technologies enable extraction and analysis of genetic information from genes derived from tumor samples stored as formalin-fixed and paraffin-embedded specimens. The Company’s principal customers include oncologists and pathologists. In addition to diagnostic testing services, the Company generates revenue from the sales of its proprietary analytical pharmacogenomic testing services of clinical trial specimens to the pharmaceutical industry. The Company’s headquarters is located in Los Angeles, California. For more information, please visit www.responsegenetics.com.

Forward-Looking Statement Notice

Except for the historical information contained herein, this press release and the statements of representatives of the Company related thereto contain or may contain, among other things, certain forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995.

Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the Company’s plans, objectives, projections, expectations and intentions, such as the ability of the Company, to provide clinical testing services to the medical community, to continue to expand its sales force, to continue to build its digital pathology initiative, to attract and retain qualified management, to continue to provide clinical trial support to pharmaceutical clients, to enter into new collaborations with pharmaceutical clients, to enter into areas of companion diagnostics, to continue to execute on its business strategy and operations, to continue to analyze cancer samples and the potential for using the results of this research to develop diagnostic tests for cancer, the usefulness of genetic information to tailor treatment to patients, successfully consummate the transactions contemplated by a purchase agreement or to successfully file a registration statement with the SEC, and other statements identified by words such as “projects,” “may,” “could,” “would,” “should,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans” or similar expressions.

These statements are based upon the current beliefs and expectations of the Company’s management and are subject to significant risks and uncertainties, including those detailed in the Company’s filings with the SEC. Actual results, including, without limitation, actual sales results, if any, or the application of funds, may differ from those set forth in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company’s control). The Company undertakes no obligation to publicly update forward-looking statements, whether because of new information, future events or otherwise, except as required by law.

Investor Relations Contact:

Company Contact:

Peter Rahmer

Thomas A. Bologna

Trout Group

Response Genetics, Inc.

646-378-2973

323-276-6060

Neuralstem Cells (CUR) Induce Significant Functional Improvement

Neuralstem Cells Induce Significant Functional Improvement In Permanent Rat Spinal Cord Injury, Cell Study Reports
Paralyzed Rats Regain Use of Lower Limbs

ROCKVILLE, Md., Sept. 13, 2012 /PRNewswire/ — Neuralstem, Inc. (NYSE MKT: CUR) announced that its neural stem cells were part of a study, “Long-Distance Growth and Connectivity of Neural Stem Cells After Severe Spinal Cord Injury: Cell-Intrinsic Mechanisms Overcome Spinal Inhibition,” published online today in a leading scientific journal CELL (http://www.cell.com/current). In the study, rats with surgically transected spinal cords, which rendered them permanently and completely paraplegic, were transplanted with Neuralstem’s spinal cord stem cells (NSI-566). The study reports that the animals recovered significant locomotor function, regaining movement in all lower extremity joints, and that the transplanted neural stem cells turned into neurons which grew a “remarkable” number of axons that extended for “very long distances” over 17 spinal segments, making connections both above and below the point of severance. These axons reached up to the cervical region (C4) and down to the lumbar region (L1). They also appeared to make reciprocal synaptic connectivity with the host rat spinal cord neurons in the gray matter for several segments below the injury.

(Logo: http://photos.prnewswire.com/prnh/20061221/DCTH007LOGO )

Further study showed that re-transecting the spinal cord immediately above the graft abolished the functional gain, indicating that the regeneration of host axons into the human stem cell graft was responsible for the functional recovery. The cells that Neuralstem contributed to the study, NSI-566, are the same cells used in the recently completed Phase 1 clinical trial for the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease). Neuralstem has also submitted an application to the FDA for a trial to treat chronic spinal cord injury with these cells.

“This study demonstrates that our neural stem cells can induce regeneration of injured spinal cord axons into the graft and serve as a bridge to reconnect to gray matter motor neurons for many spinal cord segments below the injury,” said Karl Johe, PhD, Chairman of Neuralstem’s Board of Directors and Chief Scientific Officer. “This is important in spinal cord injury because the nerve connections below the point of injury die, causing paralysis. Our cells built a bridge that received inputs from regenerating rat axons above the injury. They also sent out new human axons which made new synaptic connections with the host motor neurons in the gray matter below the injury. The fact that these cells induce regeneration of axons and partial recovery of motor function makes them relevant for testing for the treatment of human spinal cord injury.”

About the Study

In a study of 12 rats, all 12 underwent complete spinal transections at vertebrae, T3. Six of these were subsequently transplanted with Neuralstem spinal cord stem cells (NSI-566) seven days after the injury. This group was assessed over the next seven weeks and compared to the control group, which had not received transplants. The transplanted rats exhibited significant locomotor recovery, regaining movement in all lower extremity joints. A majority of the grafted cells (57%) turned into neurons. From these, the study reported, a remarkable number of axons emerged, extending both above and below the point of spinal cord lesion. These axons expressed synaptic proteins in the host gray matter, which suggests they made synaptic contact with the host spinal neurons.

About Neuralstem

Neuralstem’s patented technology enables the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells constitutively into mature, physiologically relevant human neurons and glia. Neuralstem has recently completed an FDA-approved Phase I safety clinical trial for amyotrophic lateral sclerosis (ALS), often referred to as Lou Gehrig’s disease, and has been awarded orphan status designation by the FDA.

In addition to ALS, the company is also targeting major central nervous system conditions with its NSI-566 cell therapy platform, including spinal cord injury, ischemic spastic paraplegia and chronic stroke. The company has submitted an IND (Investigational New Drug) application to the FDA for a Phase I safety trial in spinal cord injury.

Neuralstem also has the ability to generate stable human neural stem cell lines suitable for the systematic screening of large chemical libraries. Through this proprietary screening technology, Neuralstem has discovered and patented compounds that may stimulate the brain’s capacity to generate new neurons, possibly reversing the pathologies of some central nervous system conditions. The company is in a Phase Ib safety trial evaluating NSI-189, its first neurogenic small molecule compound, for the treatment of major depressive disorder (MDD). Additional indications could include chronic traumatic encephalopathy (CTE), Alzheimer’s disease, and post-traumatic stress disorder (PTSD).

For more information, please visit www.neuralstem.com or connect with us on Twitter and Facebook.

Cautionary Statement Regarding Forward Looking Information

This news release may contain forward-looking statements made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements in this press release regarding potential applications of Neuralstem’s technologies constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in Neuralstem’s periodic reports, including the annual report on Form 10-K for the year ended December 31, 2011 and the quarterly report on Form 10-Q for the period ended June 30, 2012.

Mindspeed (MSPD) and SpiderCloud Innovate on Scalable Enterprise 3G Small Cells

Mindspeed Technologies, Inc. (NASDAQ: MSPD), the leading supplier of small cell technology, today announced that it has co-developed a customized baseband processor with SpiderCloud Wireless featuring software, self-organizing and scalable system features by SpiderCloud. The new processor solution opens the door for mobile operators to roll out scalable deployments of robust indoor 3G systems for medium to large enterprise customers worldwide.

The SpiderCloud Wireless Enterprise Radio Access Network (E-RAN) system uses SpiderCloud’s highly optimized software stack that includes its own physical layer software (PHY) implementation on Mindspeed’s system-on-chip (SoC). The PHY plays a critical role in solving mobility and interference problems of radio nodes, which are controlled and powered by SpiderCloud’s enterprise premises-based services node.

The self-organizing E-RAN, which can be installed in just days by a mobile operator or its partners, delivers reliable 3G coverage and capacity for 100 to 1000s of people using any existing Ethernet Local Area Network (LAN) for backhaul and enterprise services integration, with full mobility and cell-to-cell handoff and synchronization with the operator’s macro cellular network.

“Small cells have quickly become a recognized part of carrier network plans for both metro area and residential services. Still, despite a good deal of focus, the challenges of the corporate environment have been tougher to meet,” said Peter Jarich, Vice President, Consumer and Infrastructure at Current Analysis. “This co-operation, and the level of development that has gone into it, is further evidence of how complex the enterprise segment truly is. More generally, it is an indication of how the small cell market continues to innovate and the opportunities continue to grow.”

“3G small cells are being deployed in homes, small enterprises and outside in metropolitan areas, but until now, the industry has not been able to deliver a true ‘enterprise-grade’ system,” said Raouf Y. Halim, chief executive officer at Mindspeed. “It took years of developments and innovative thinking by Mindspeed and SpiderCloud Wireless to enable such a system, and we’re proud to take part in unlocking the enterprise opportunity for mobile operators.”

Mindspeed is the leader in small cell technology, with 70% share of the high-speed packet access (HSPA) market according to data from ABI Research. Mindspeed is the only small cell SoC company that has demonstrated support for both HSPA and LTE in its small cell SoCs, and the only one to have shown both frequency-division duplexing (FDD) LTE and time-division LTE (TD-LTE) solutions.

“Mindspeed’s technology leadership and ability to provide custom features has helped us bring to market a unique and scalable 3G small cell platform for enterprise deployments by mobile operators,” added Behrooz Parsay, senior vice president of engineering and operations with SpiderCloud Wireless. “SpiderCloud has invested significant time and resources to commercialize a unique PHY, MAC and upper layers solution. We’ve worked closely with Mindspeed in developing our own PHY as part of this new enterprise small cell network, and the combination of this with Mindspeed’s expertise has resulted in a truly market leading system.”

About Mindspeed Technologies

Mindspeed Technologies (NASDAQ: MSPD) is a leading provider of network infrastructure semiconductor solutions to the communications industry. The company’s low-power system-on-chip (SoC) products are helping to drive video, voice and data applications in worldwide fiber-optic networks and enable advanced processing for 3G and long-term evolution (LTE) mobile networks. The company’s high-performance analog products are used in a variety of optical, enterprise, industrial and video transport systems. Mindspeed’s products are sold to original equipment manufacturers (OEMs) around the globe.

To learn more, please visit www.mindspeed.com. Company news and updates are also posted at www.twitter.com/mindspeed.

About SpiderCloud Wireless, Inc.

SpiderCloud Wireless develops breakthrough, small-cell network platforms that allow mobile operators to deliver unprecedented cellular coverage, capacity and smart applications to enterprises. SpiderCloud is based in San Jose, California and is backed by investors Charles River Ventures, Matrix Partners, Opus Capital and Shasta Ventures. For more information, follow the company on twitter at www.twitter.com/spidercloud_inc or visit www.spidercloud.com.

SpiderCloud Wireless is a registered trademark and SmartCloud a trademark of SpiderCloud Wireless, Inc. ©2012 SpiderCloud Wireless, Inc.

Point.360 (PTSX) Announces Fourth Fiscal Quarter and Fiscal 2012 Results

BURBANK, Calif., Sept. 12, 2012 /PRNewswire/ — Point.360 (NASDAQ: PTSX), a leading provider of integrated media management services, today announced results for the three and twelve month periods ended June 30, 2012, including sales of $35.0 million and income per share of $0.04 for the twelve months ended June 30, 2012. For the quarter ended June 30, 2012, the Company’s sales were $9.0 million generating income of $0.06 per share. The Company also reported $4.5 million of earnings before interest, taxes, depreciation and amortization and non-cash charges (EBITDAN) for the twelve-month period, and EBITDAN of $1.5 million for the three-month period.

Haig S. Bagerdjian, the Company’s Chairman, President and Chief Executive Officer said: “We are pleased with the Company’s return to profitability in the just ended fiscal year. Our cash flow is improving. We have entered into a significant financing arrangement with a major bank. We have also taken major steps to match our capabilities to our customers’ needs by changing facility configurations and lowering costs.”

Mr. Bagerdjian continued: “We are no longer subject to the 2007 noncompetition agreement associated with the sale of our advertising distribution business. Realizing that this market has changed over the last five years, we intend to explore how to take advantage of this opportunity.”

Revenues

Revenue for the quarter ended June 30, 2012 totaled $9.0 million compared to $8.6 million in the same quarter last year. Revenues for the twelve months ended June 30, 2012 were $35.0 million compared to $35.2 million last year. Fluctuations between the periods were due to the timing of service deliveries.

Gross Margin

In the fourth quarter of fiscal 2012, gross margin was $3.6 million (40% of sales), compared to $2.8 million (32% of sales) in the prior year’s fourth quarter. For fiscal 2012, gross margin was $12.9 million or 37% of sales, compared to $10.9 million, or 31% of sales in last year.

Selling, General and Administrative and Other Expenses

For the fourth quarter of fiscal 2012, SG&A expenses were $2.9 million, or 32% of sales, compared to $3.0 million, or 35% of sales, in the fourth quarter of last year. For the twelve months ended June 30, 2012, SG&A expenses were $12.1 million (35% of sales) compared to $13.2 million (37% of sales) last year. SG&A personnel costs have been reduced $0.3 million in the current twelve month period, when compared to the prior year period.

Research and development costs associated with Movie>Q and other projects were $0.4 million in the twelve month period ended June 30, 2011.

During fiscal 2011, the Company decided not to use a portion of the originally-acquired Movie>Q assets, specifically those related to kiosk (vending) machines, in the Movie>Q project. In the twelve month period ended June 30, 2011, the Company recorded a related $684,000 non-cash impairment charge.

Interest expense was $0.2 million and $0.8 million for the three and twelve month periods ended June 30, 2012, and $0.2 million and $0.9 million in the three and twelve month periods ended June 30, 2011. In last year’s twelve-month period, the Company received $0.1 million of interest income from the Internal Revenue Service associated with a $1.5 million tax refund.

Other income in all periods represents sublease income and gain on sale of fixed assets. In the 2012 twelve month period, other income also included a $0.1 million discount on debt repayment. In the prior year twelve-month period, the Company also received $1.0 million from the settlement of a claim. In the prior year twelve-month period, other income was partially offset by a put option expense of $0.1 million.

Operating Income (Loss)

Operating income was $0.7 million in the fourth quarter of fiscal 2012 compared to a loss of $0.3 million in last year’s fourth quarter. For the twelve month period ended June 30, 2012, operating income was $0.8 million compared to a loss of $3.4 million in the prior year’s twelve month period.

Net Income (Loss)

For the fourth quarter of fiscal 2012, the Company reported net income of $0.6 million ($0.06 per share) compared to a net loss of $0.4 million ($0.04 per share) in the same period last year. For the twelve months ended June 30, 2012, the Company reported net income of $0.4 million ($0.04 per share) compared to a net loss of $2.8 million ($0.26 per share) in the prior year period.

Earnings Before Interest, Taxes, Depreciation, Amortization and Non-Cash Charges (EBITDAN)*

The following table reconciles the Company’s EBITDAN to net income (loss) which is the most directly comparable financial measure under Generally Accepted Accounting Principles (“GAAP”):

Computation of EBITDAN (unaudited)*

Three Months Ended

Twelve Months Ended

June 30,

June 30,

2011

2012

2011

2012

Net income (loss)

$(420,000)

$ 615,000

$(2,811,000)

$ 448,000

Interest (net)

247,000

­ ­­197,000

804,000

814,000

Income taxes

—

—

—

—

Depreciation & amortization

833,000

674,000

3,578,000

2,938,000

Other non-cash charges:

Bad debt expense

10,000

8,000

36,000

35,000

Stock based compensation

85,000

43,000

317,000

294,000

Impairment charges

—

—

684,000

—

EBITDAN

$755,000

$1,537,000

$2,608,000

$4,529,000

In the year ended June 30, 2011, the Company recognized $1 million of income from the settlement of a claim. Excluding the claim income, EBITDAN for the twelve month period ended June 30, 2011 was $1,608,000.

Consolidated Statements of Operations (unaudited) *

The table below summarizes results for the three and nine month periods ended June 30, 2011 and 2012:

Three Months Ended

June 30,

Twelve Months Ended

June 30,

2011

2012

2011

2012

Revenues

$ 8,622,000

$ 8,951,000

$ 35,222,000

$ 34,960,000

Cost of services sold

(5,858,000)

5,368,000

(24,343,000)

(22,064,000)

Gross profit

2,764,000

3,583,000

10,879,000

12,896,000

Selling, general and administrative expense

(3,015,000)

(2,864,000)

(13,197,000)

(12,074,000)

Research and development expense

–

–

(352,000)

–

Impairment charge

–

–

(684,000)

–

Operating income (loss)

(251,000)

719,000

(3,354,000)

822,000

Interest expense

(247,000)

(197,000)

(857,000)

(834,000)

Interest income

–

–

53,000

20,000

Other income

78,000

93,000

1,347,000

440,000

Income (loss) before income taxes

(420,000)

615,000

(2,811,000)

448,000

Provision for income taxes

–

–

–

–

Net income (loss)

$ (420,000)

$ 615,000

$ (2,811,000)

$ 448,000

Income (loss) per share:

Basic:

Net income (loss)

$ (0.04)

$ 0.06

$ (0.26)

$ 0.04

Weighted average number of shares

10,529,650

10,513,166

10,646,728

10,513,166

Diluted:

Net income (loss)

$ (0.04)

$ 0.06

$ (0.26)

$ 0.04

Weighted average number of shares

including the dilutive effect of stock

options

10,529,650

10,513,166

10,646,728

10,523,446

Selected Balance Sheet Statistics (unaudited)*

June 30,

2011

June 30,

2012

Working Capital

$ 2,885,000

$ 4,261,000

Property and equipment, net

17,153,000

17,475,000

Total assets

25,395,000

25,971,000

Current portion of long term debt

1,709,000

172,000

Long-term debt, net of current portion

9,711,000

9,236,000

Shareholder’s equity

9,489,000

10,231,000

*The consolidated statements of operations, computation of EBITDAN and presentation of balance sheet statistics do not represent the results of operations or the financial position of the Company in accordance with generally accepted accounting principles (GAAP), and are not to be considered as alternatives to the balance sheet, statement of income, operating income, net income or any other GAAP measurements as an indicator of operating performance or financial position. Not all companies calculate such statistics in the same fashion and, therefore, the statistics may not be comparable to other similarly titled measures of other companies. Management believes that these computations provide additional useful analytical information to investors.

About Point.360

Point.360 (PTSX) is a value add service organization specializing in content creation, manipulation and distribution processes integrating complex technologies to solve problems in the life cycle of Rich Media. With locations in greater Los Angeles, Point.360 performs high and standard definition audio and video post production, creates virtual effects and archives and distributes physical and electronic Rich Media content worldwide, serving studios, independent producers, corporations, non-profit organizations and governmental and creative agencies. Point.360 provides the services necessary to edit, master, reformat and archive clients’ audio and video content, including television programming, feature films and movie trailers. Point.360’s interconnected facilities provide service coverage to all major U.S. media centers. The Company also rents and sells DVDs and video games directly to consumers through its Movie>Q retail stores. See www.Point360.com and www.MovieQ.com.

Forward-looking Statements

Certain statements in Point.360 press releases may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, without limitation, statements regarding (i) the Company’s projected revenues, earnings, cash flow and EBITDA; (ii) planned focus on internal growth and acquisitions; (iii) reduction of facilities and actions to streamline operations; (iv) actions being taken to reduce costs and improve customer service and (v) new business and new acquisitions. Please also refer to the risk factors described in the Company’s SEC filings, including its annual reports on Form 10-K. Such statements are inherently subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements of the Company to be materially different from those expected or anticipated in the forward-looking statements. In addition to the factors described in the Company’s SEC filings, the following factors, among others, could cause actual results to differ materially from those expressed herein: (a) lower than expected net sales, operating income and earnings; (b) less than expected growth; (c) actions of competitors including business combinations, technological breakthroughs, new product offerings and promotional successes; (d) the risk that anticipated new business may not occur or be delayed; (e) the risk of inefficiencies that could arise due to top level management changes and (f) general economic and political conditions that adversely impact the Company’s customers’ willingness or ability to purchase or pay for services from the Company. The Company has no responsibility to update forward-looking statements contained herein to reflect events or circumstances occurring after the date of this release.

Powerwave Technologies (PWAV) Announces New Credit Agreement

Powerwave Technologies, Inc. (Nasdaq:PWAV), a global supplier of end-to-end wireless solutions for wireless communications networks, today announced that it has entered into a new $50 million senior secured credit agreement with P-Wave Holdings, LLC, an affiliate of The Gores Group. Under the credit agreement, the lenders advanced $35 million to the Company, less fees and expenses, and agreed to loan an additional $15 million to the Company upon request from the Company subject to the fulfillment of certain conditions. The new credit agreement also includes an accordion feature that allows the Company to request up to an additional $100 million in term loans from the lenders, which they may advance in their discretion. Proceeds from advances under the new credit agreement will be used to finance working capital and for general corporate purposes.

In connection with this initial loan, the lender received warrants to purchase a total of 2,625,000 shares of the Company’s common stock with an exercise price for the warrants of $0.50 per share, which exercise price is subject to adjustment under the terms of the warrant.

Detailed information regarding the credit agreement and the other transactions contemplated in the credit agreement is included in the Company’s Current Report on Form 8-K dated September 12, 2012, as filed with the Securities and Exchange Commission.

No Solicitation; Unregistered Securities

This press release does not constitute an offer to sell or the solicitation of an offer to buy any security. Neither the warrants nor the shares of common stock underlying such warrants have been registered under the Securities Act of 1933, as amended, or any applicable state securities laws, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act of 1933, as amended.

Company Background

Powerwave Technologies, Inc., is a global supplier of end-to-end wireless solutions for wireless communications networks. Powerwave designs, manufactures and markets a comprehensive suite of wireless solutions, including antennas, base station products and advanced coverage solutions, utilized in all major wireless network protocols and frequencies, including Next Generation Networks in 4G technology, such as LTE. Corporate headquarters are located at 1801 E. St. Andrew Place, Santa Ana, Calif. 92705. For more information on Powerwave’s advanced wireless coverage and capacity solutions, please call (888)-PWR-WAVE (797-9283) or visit our web site at www.powerwave.com. Powerwave, Powerwave Technologies and the Powerwave logo are registered trademarks of Powerwave Technologies, Inc.

SEFE (SEFE) Completes Initial Prototype of Corona Discharge Electrostatic Motor

SEFE, Inc. (OTCBB/OTCQB: SEFE) (the “Company”), a solutions-driven company developing products and technologies that improve worldwide access to basic resources, including energy, food and water, today announces the completion of a low-power corona discharge motor prototype at its headquarters in Boulder, Colo. This type of electrostatic motor is well suited for medium and high power applications, and represents an additional avenue the R&D team is pursuing for the conversion of atmospheric electricity.

The corona discharge motor employs a dielectric cylinder lined on the inside with thin metallic foil. The motor is surrounded by multiple alternating polarity corona discharge terminals that spray charge onto the dielectric surface when a high voltage is applied. The grounded poles of the motor serve as a current sink. Corona discharge enables the device to handle much higher DC currents than traditional electrostatic motors.

“Our prototype motor serves as a low power proof of concept for this type of electrostatic motor,” stated SEFE Director of Engineering Michael Hurowitz. “We’ll be working to increase the capabilities of these motors to handle much stronger currents as we move forward.”

About SEFE, Inc.

SEFE focuses on pushing the boundaries of what’s possible, embracing innovation and employing the cutting-edge to solve problems, and offering sustainable solutions to a world hungry for invention, direction and leadership. SEFE is technology- and solutions-driven, focusing on developing inventions that provide a real-world impact and true profitability. So, success is measured by both a sustainable return on investment, as well as a project’s sustainability from an environmental perspective.

For more information, visit www.SEFElectric.com.

Forward-Looking Statements

This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance or achievements to differ materially from anticipated results, performance or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.

Dehaier Medical (DHRM) Receives SFDA Approval for DHR-CPAP-C5

BEIJING, Sept. 11, 2012 /PRNewswire-FirstCall/ — Dehaier Medical Systems Ltd. (NASDAQ: DHRM) (“Dehaier”), an emerging leader in the development, assembly, marketing and sale of medical devices and homecare medical products in China, today announced that it has obtained State Food and Drug Administration approval for DHR-CPAP-C5, one of Dehaier’s major proprietary homecare medical devices. The period of validity for the SFDA approval is four years.

(Logo: http://photos.prnewswire.com/prnh/20100422/CNTH001LOGO)

Continuous Positive Airway Pressure (CPAP) has become the first line of treatment for Obstructive Sleep Apnea Syndrome (OSAS) and for some forms of central sleep apnea. CPAP works by creating a pneumatic splint for the upper airway. A flow generator sends pressurized air through air tubing and a mask (usually a nasal mask) and through the nose to the upper airway. The pressurized air prevents the soft tissues of the upper airway from narrowing and collapsing. For proper CPAP treatment, patient can set high enough flow generator pressures to prevent apneas and hypopneas during all sleep stages and in all sleep positions. The SFDA approval indicated that DHR-CPAP-C5 has met the national health and safety standards and it will be launched in China soon.

Dehaier is committed to offering all-in-one solution for diagnosis, treatment and assessment of Obstructive Sleep Apnea Syndrome (OSAS). Currently, DHR-998 (used for diagnosis and treatment evaluation) has been put into the international market upon the receive of the CE Mark in 2011. Dehaier will continue to strengthen the domestic marketing effort for its high margin, proprietary homecare medical products and at the same time, explore new business model and strategic partnership.

“We are excited about the recent SFDA approval for DHR-CPAP-C5 which is another important step towards providing complete solution to fight sleep disorders.” Commented by Mr. Ping Chen, Chairman and Chief Executive Officer of Dehaier Medical, “Developing and expanding the market share of homecare medical equipment has become one of the Dehaier’s critical business strategies because we believe in the tremendous growth potential in Chinese homecare medical market. With great efforts on R&D, product upgrade, diversification of product mix and expansion of patents, Dehaier is well prepared to not only educate the Chinese consumer about the homecare concept, but also serve the upcoming explosive demand for homecare medical equipment. We will seize any chance to become one of leading players in this promising market.”

About Dehaier Medical Systems Ltd.

Dehaier is an emerging leader in the development, assembly, marketing and sale of medical products, including respiratory and oxygen homecare medical products. The company develops and assembles its own branded medical devices and homecare medical products from third-party components. The company also distributes products designed and manufactured by other companies, including medical devices from IMD (Italy), Welch Allyn (USA), HEYER (Germany), Timesco (UK), eVent Medical (US) and JMS (Japan). Dehaier’s technology is based on six patents, nine software copyrights and proprietary technology. More information may be found at http://www.dehaier.com.cn

Forward-looking Statements

This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events, government approvals or performance, and underlying assumptions and other statements that are other than statements of historical facts, including in particular any implications regarding the SFDA approval for DHR-CPAP-C5. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, future developments in payment for and demand for medical equipment and services, implementation of and performance under the joint venture agreement by all parties, and other risks contained in reports filed by the company with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the company, are expressly qualified by the cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.

Contact Us

Dehaier Medical Systems Limited
Surie Liu
+86 10-5166-0080
lius@dehaier.com.cn

Dehaier Medical Systems Limited
Tina He
+86 10-5166-0080
hexw@dehaier.com.cn

Cell Therapeutics (CTIC) Announces European Launch of Pixuvri for Non-Hodgkin B-Cell Lymphoma

Cell Therapeutics, Inc. (“CTI”) (NASDAQ and MTA: CTIC), a company focused on translating science into novel cancer therapies, today announced the initiation of the commercial launch of Pixuvri® in the European Union (“E.U.”) with entry into Sweden, Denmark and Finland in September, to be followed by Austria and Norway in early October 2012 and Germany, United Kingdom and the Netherlands in November 2012. CTI plans to expand availability to France, Italy and Spain as well as other European countries in 2013. Pixuvri was granted conditional marketing authorization by the European Commission in May 2012 and is the first medicinal product licensed in the E.U. to treat adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin Lymphoma (“NHL”). In the E.U., there are approximately 37,000 new cases of aggressive B-cell NHL every year.[1],[2]

“Patients with late-stage aggressive NHL who are not eligible for, or who have not responded to, second line therapy, have very limited treatment options and a bleak outlook, with average survival of less than a year,” commented Dr. Ruth Pettengell, Consultant Hemato-Oncologist at St George’s Hospital, London and principal investigator of the Phase III EXTEND study. “The evidence for Pixuvri demonstrates improved efficacy over current treatment options, but without the cardiotoxicity of anthracyclines. By addressing this unmet need, Pixuvri is an important new treatment option for physicians treating this group of patients.”

In the EXTEND (Expanding the reach of anthracyclines with piXanTronE in relapsed or refractory aggressive NHL Disease) study for Pixuvri, when compared with other active single-agent treatments, more patients on Pixuvri achieved a complete response or unconfirmed complete response, and also survived for longer before their disease progressed.[3] Prior to the approval of Pixuvri there was no standard of care for treating patients who failed front line and second line therapy for aggressive B cell NHL. The EXTEND trial is the only randomized controlled clinical study in this patient population establishing the standard of care for this patient population.

“We are pleased to be able to offer the first meaningful treatment option for physicians treating those patients with multiply relapsed and refractory aggressive NHL,” stated James A. Bianco, M.D., President and CEO of CTI. “CTI looks forward to making this innovative product available to healthcare providers across the European Union.”

About Pixuvri (pixantrone)

Pixuvri is a novel aza-anthracenedione with unique structural and physio-chemical properties. Unlike related compounds, Pixuvri forms stable DNA adducts and has demonstrated superior anti-lymphoma activity compared to related compounds[4],[5] Pixuvri was structurally designed so that it cannot bind iron and perpetuate oxygen radical production or form a long-lived hydroxyl metabolite – both of which are the putative mechanisms for anthracycline-induced acute and chronic cardiotoxicity.[6] These novel pharmacologic properties allow Pixuvri to be administered to patients with near maximal lifetime exposure to anthracyclines without unacceptable rates of cardiotoxicity.

In May 2012, Pixuvri received conditional marketing authorization in the E.U. as monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive NHL. The benefit of pixantrone treatment has not been established in patients when used as fifth line or greater chemotherapy in patients who are refractory to last therapy. Please refer to the Summary of Product Characteristics (“SmPC”) for the full prescribing information, including the safety and efficacy profile of Pixuvri in the approved indication. The SmPC is available at http://ec.europa.eu/health/documents/community-register/html/h764.htm#ProcList.

CTI is currently accruing patients into a Phase 3 trial comparing pixantrone and rituximab with gemcitabine and rituximab in the setting of aggressive B-cell NHL. European sites will be participating in this study later this year.

Pixuvri is available in the E.U. through Named Patient Programs in those countries where it is not available commercially.

Pixuvri does not have marketing approval in the United States.

About Conditional Marketing Authorization

Similar to accelerated approval regulations in the United States, conditional marketing authorizations are granted in the E.U. to medicinal products with a positive benefit/risk assessment that address unmet medical needs and whose availability would result in a significant public health benefit as determined by the assessment conducted by the European Medicines Agency. A conditional marketing authorization is renewable annually. Under the provisions of the conditional marketing authorisation for Pixuvri, CTI will be required to complete a post-marketing study aimed at confirming the clinical benefit previously observed.

The European Medicines Agency’s (the “EMA”) Committee for Medicinal Products for Human Use has accepted PIX306, CTI’s ongoing randomized controlled phase III clinical trial, which compares Pixuvri-rituximab to gemcitabine-rituximab in patients who have relapsed after one to three prior regimens for aggressive B‑cell NHL and who are not eligible for autologous stem cell transplant. As a condition of approval, CTI has agreed to have available the PIX306 clinical trial results by June 2015.

About Non-Hodgkin’s Lymphoma

NHL is caused by the abnormal proliferation of lymphocytes, cells key to the functioning of the immune system. It usually originates in lymph nodes and spreads through the lymphatic system. NHL can be broadly classified into two main forms-aggressive and indolent NHL. Aggressive NHL is a rapidly growing form of the disease that moves into advanced stages much faster than indolent NHL, which progresses more slowly.

There are many subtypes of NHL, but aggressive B cell NHL is the most common and accounts for about 50% of NHL cases.[2] After initial therapy for aggressive NHL with anthracycline-based combination therapy, one-third of patients typically develop progressive disease.[7] Approximately half of these patients are likely to be eligible for intensive second-line treatment and stem cell transplantation, although 50% are expected not to respond.[7] For those patients who fail to respond or relapse following second-line treatment, treatment options are limited, and usually palliative only.[7] Pixuvri is the first treatment to receive E.U. regulatory approval for treatment of patients with multiply relapsed or refractory aggressive B-cell NHL.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit http://www.CellTherapeutics.com.

Sign up for email alerts and get RSS feeds at our Web site, http://www.CellTherapeutics.com/investors_alert

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results and the market price of CTI’s securities. Specifically, the risks and uncertainties that could affect the development of Pixuvri include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and with Pixuvri in particular including, without limitation, the potential failure of Pixuvri to prove safe and effective for the treatment of relapsed or refractory NHL and/or other tumors as determined by the U.S. Food and Drug Administration, that CTI may not market and commercialize Pixuvri in the E.U. as planned, that CTI may not launch Pixuvri in the E.U. this year as planned, that CTI may not be able to complete the PIX306 clinical trial of Pixuvri-rituximab compared to gemcitabine-rituximab in patients who have relapsed after 1 to 3 prior regimens for aggressive B cell NHL and who are not eligible for autologous stem cell transplant by June 2015 or at all as required by the EMA or have the results of such trial available by June 2015 or at all, that CTI may not be able complete a post-marketing study aimed at confirming the clinical benefit observed in the PIX301 trial, that the conditional marketing authorization for Pixuvri may not be renewed, that CTI cannot predict or guarantee the pace or geography of enrollment of its clinical trials or the total number of patients enrolled, that CTI’s average net operating burn rate may increase and CTI’s ability to continue to raise capital as needed to fund its operations in general, and, including, without limitation, competitive factors, technological developments, costs of developing, producing, and selling Pixuvri, and the risk factors listed or described from time to time in CTI’s filings with the Securities and Exchange Commission including, without limitation, CTI’s most recent filings on Forms 10-K, 8-K, and 10-Q. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.

References

European Cancer Observatory, Cancer Fact Sheets, 2008
Harris NL, et al. Ann Oncol. 1999;10(12):1419-32
Pettengell R, Coiffier B, Narayanan G et al. Lancet 2012. Published online May 30th 2012. DOI:10:1-16/S1470-2045(12)70212-7
Cavalletti E, Crippa L, Mainardi P et al. Invest New Drugs 2007;25:187-95
Hagemeister FB. Cancer Chemother Pharmacol 2002;49(suppl 1):S13-20
Cavalletti E, Crippa L, Mainardi P et al. Invest New Drugs 2007;25:187-95
Friedberg ASH Education Book 2011;1:498-505

Media Contact:
Dan Eramian
T: +1-206-272-4343
C: +1-206-854-1200
E: deramian@ctiseattle.com
http://www.CellTherapeutics.com/press_room

Investors Contact:
Ed Bell
T: +1-206-282-7100
F: +1-206-272-4434
E: invest@ctiseattle.com
http://www.CellTherapeutics.com/investors

WSB Holdings (WSB) Investigation by Levi & Korsinsky, LLP

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces Investigation into Possible Breaches of Fiduciary Duty by the Board of WSB Holdings, Inc. in Connection with the Sale of the Company to Old Line Bancshares, Inc.

NEW YORK, Sept. 11, 2012 /PRNewswire/ — Levi & Korsinsky is investigating the Board of Directors of WSB Holdings, Inc. (“WSB” or the “Company”) (Nasdaq: WSB) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Old Line Bancshares, Inc. (“Old Line”) (Nasdaq: OLBK).

(Logo: http://photos.prnewswire.com/prnh/20120409/MM84375LOGO )

Click here to learn more about the investigation: http://zlk.9nl.com/wsb, or call: 877-363-5972. There is no cost or obligation to you.

Under the terms of the transaction, WSB shareholders will receive approximately $6.12 per share in cash and stock. The transaction has a total approximate value of $49 million. The investigation concerns whether the WSB Board of Directors breached their fiduciary duties to WSB stockholders by failing to adequately shop the Company before entering into this transaction and whether Old Line is underpaying for WSB shares, thus unlawfully harming WSB stockholders. In particular, the Company has reported a book value of $6.90 per share, for the most recent quarter.

If you own common stock in WSB and wish to obtain additional information, please contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit : http://zlk.9nl.com/wsb.

Levi & Korsinsky is a national firm with offices in New York and Washington D.C. The firm has extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph Levi, Esq.
Eduard Korsinsky, Esq.
30 Broad Street – 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com

Hydrocarb Partners with Duma Energy (DUMA) to Explore for World Class Reserves in Africa Concession

Hydrocarb Energy Corporation is pleased to announce the completion of a farm-out agreement to Duma Energy Corporation (OTCBB:DUMA). Houston-based Duma, with current production in the Gulf Coast, acquires a 39% working interest in Owambo blocks 1714A, 1715, 1814A, and 1815A in northern Namibia.

Kent Watts, Hydrocarb’s Chief Executive, stated, “Our vast and underexplored concession shows tremendous potential based on the data available to date. We have reviewed a third party report already estimating over a billion barrels of un-risked resource potential out of a single identified structure. The Duma partnership allows us to move aggressively towards our ultimate goal, to make a major discovery in Namibia. We anticipate building on new technical findings as the exploration process unfolds.”

The concession, over 5 million acres, is roughly the size of Massachusetts. Northern Namibia has all of the key ingredients for becoming a major oil province, including good reservoir and source rocks. Hydrocarb, as 51% owner, retains its role as operator on all blocks. The new partnership includes NAMCOR, the Namibian National Oil Company as a 10% partner, and Duma at 39%. The commercial terms for the Owambo Petroleum Contract are highly favorable with reasonable onshore operating and exploration costs. Namibia, an English speaking democracy, has proven to be one of the most stable countries on the continent.

Despite its extensive resources, Africa remains greatly under-explored. Recent discoveries of large oil and gas reserves by companies such as Kosmos (NYSE:KOS) and Tullow PLC (LON:TLW) suggest oil and gas production in Africa may be on the verge of dramatic growth. Major and independent players such as Chevron (NYSE:CVX) and Hyperdynamics (NYSE:HDY) have secured huge acreage positions and are budgeting billions of dollars for exploration.

Duma Energy Corp.’s Chief Executive, Jeremy Driver, commented, “Our concession is in the Namibian portion of the Owambo Basin which extends into southern Angola and is one of the largest unexplored onshore basins in Africa.” He went on to say, “This partnership with Hydrocarb fits our core strategy to continuously develop profitable production domestically while also participating in high impact opportunities internationally that have world class potential.”

About Hydrocarb Corp. is a privately held energy exploration and production company targeting major under-explored oil and gas projects in emerging, highly prospective regions of the world. With headquarters in Houston, Texas we maintain offices in Abu Dhabi, UAE and Windhoek, Namibia. For further information: www.hydrocarb.com

About Duma Energy Corp.

Duma Energy Corp. (DUMA) is an aggressive growth company actively producing oil and gas in the continental United States, both on and offshore. Duma also has a significant interest in a 5.3-million acre concession in the Republic of Namibia in Southern Africa. Duma Energy will continue increasing revenue, cash flow, and reserves to fund its aggressive growth through acquisition and participation in projects with the potential of providing exponential returns for shareholders. Further information can be found on the Company’s website at www.duma.com